CA2378010A1 - Crystallization and structure determination of staphylococcus aureus thymidylate kinase - Google Patents
Crystallization and structure determination of staphylococcus aureus thymidylate kinase Download PDFInfo
- Publication number
- CA2378010A1 CA2378010A1 CA002378010A CA2378010A CA2378010A1 CA 2378010 A1 CA2378010 A1 CA 2378010A1 CA 002378010 A CA002378010 A CA 002378010A CA 2378010 A CA2378010 A CA 2378010A CA 2378010 A1 CA2378010 A1 CA 2378010A1
- Authority
- CA
- Canada
- Prior art keywords
- molecule
- molecular complex
- aureus
- thymidylate kinase
- binding pocket
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101900110165 Staphylococcus aureus Thymidylate kinase Proteins 0.000 title abstract description 4
- 238000002425 crystallisation Methods 0.000 title description 12
- 230000008025 crystallization Effects 0.000 title description 11
- 239000013078 crystal Substances 0.000 claims abstract description 63
- 239000003112 inhibitor Substances 0.000 claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 34
- 102100037357 Thymidylate kinase Human genes 0.000 claims description 285
- 108010000742 dTMP kinase Proteins 0.000 claims description 285
- 230000027455 binding Effects 0.000 claims description 173
- 150000001413 amino acids Chemical class 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 91
- 239000000758 substrate Substances 0.000 claims description 85
- 150000005829 chemical entities Chemical class 0.000 claims description 80
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims description 69
- 108091000080 Phosphotransferase Proteins 0.000 claims description 24
- 102000020233 phosphotransferase Human genes 0.000 claims description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 18
- 238000005094 computer simulation Methods 0.000 claims description 18
- 230000003993 interaction Effects 0.000 claims description 16
- 238000002441 X-ray diffraction Methods 0.000 claims description 15
- 238000013500 data storage Methods 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 11
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical group C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000002452 interceptive effect Effects 0.000 claims description 10
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims description 9
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 229960002718 selenomethionine Drugs 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000011232 storage material Substances 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 claims 10
- 238000007634 remodeling Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 63
- 125000004429 atom Chemical group 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 28
- 241000588724 Escherichia coli Species 0.000 description 24
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 23
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 23
- 229960001456 adenosine triphosphate Drugs 0.000 description 23
- 239000003446 ligand Substances 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 230000002547 anomalous effect Effects 0.000 description 9
- UJLXYODCHAELLY-XLPZGREQSA-N dTDP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 UJLXYODCHAELLY-XLPZGREQSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000012900 molecular simulation Methods 0.000 description 9
- WFDDMRRZEHUPCP-UHFFFAOYSA-N Nc1ccc(Sc2ccc(Sc3ccc(N)cc3)s2)cc1 Chemical compound Nc1ccc(Sc2ccc(Sc3ccc(N)cc3)s2)cc1 WFDDMRRZEHUPCP-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000470 constituent Substances 0.000 description 7
- 238000009510 drug design Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000013480 data collection Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 230000009881 electrostatic interaction Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 3
- QOYVAFWJURKBJG-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 QOYVAFWJURKBJG-XLPZGREQSA-N 0.000 description 3
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000007806 chemical reaction intermediate Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000001177 diphosphate Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 108010078274 isoleucylvaline Proteins 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 235000011649 selenium Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 2
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 2
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 2
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 2
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 2
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000002017 high-resolution X-ray diffraction Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229910021654 trace metal Inorganic materials 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- IGXNPQWXIRIGBF-KEOOTSPTSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IGXNPQWXIRIGBF-KEOOTSPTSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- VXRAAUKUZQYZRW-UHFFFAOYSA-N 3'-N'-Acetylfusarochromanone Chemical compound O1C(C)(C)CC(=O)C2=C(N)C(C(=O)CC(CO)NC(=O)C)=CC=C21 VXRAAUKUZQYZRW-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- XEXJJJRVTFGWIC-FXQIFTODSA-N Ala-Asn-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XEXJJJRVTFGWIC-FXQIFTODSA-N 0.000 description 1
- NKJBKNVQHBZUIX-ACZMJKKPSA-N Ala-Gln-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKJBKNVQHBZUIX-ACZMJKKPSA-N 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 1
- RUXQNKVQSKOOBS-JURCDPSOSA-N Ala-Phe-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RUXQNKVQSKOOBS-JURCDPSOSA-N 0.000 description 1
- HCBKAOZYACJUEF-XQXXSGGOSA-N Ala-Thr-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O HCBKAOZYACJUEF-XQXXSGGOSA-N 0.000 description 1
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- XKHLBBQNPSOGPI-GUBZILKMSA-N Ala-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N XKHLBBQNPSOGPI-GUBZILKMSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 101100309713 Arabidopsis thaliana SD129 gene Proteins 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- DXQIQUIQYAGRCC-CIUDSAMLSA-N Arg-Asp-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)CN=C(N)N DXQIQUIQYAGRCC-CIUDSAMLSA-N 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 1
- BMNVSPMWMICFRV-DCAQKATOSA-N Arg-His-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CN=CN1 BMNVSPMWMICFRV-DCAQKATOSA-N 0.000 description 1
- AGVNTAUPLWIQEN-ZPFDUUQYSA-N Arg-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AGVNTAUPLWIQEN-ZPFDUUQYSA-N 0.000 description 1
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- MFFOYNGMOYFPBD-DCAQKATOSA-N Asn-Arg-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MFFOYNGMOYFPBD-DCAQKATOSA-N 0.000 description 1
- SPCONPVIDFMDJI-QSFUFRPTSA-N Asn-Ile-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O SPCONPVIDFMDJI-QSFUFRPTSA-N 0.000 description 1
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
- RGKKALNPOYURGE-ZKWXMUAHSA-N Asp-Ala-Val Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O RGKKALNPOYURGE-ZKWXMUAHSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 1
- YBMUFUWSMIKJQA-GUBZILKMSA-N Asp-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N YBMUFUWSMIKJQA-GUBZILKMSA-N 0.000 description 1
- CSEJMKNZDCJYGJ-XHNCKOQMSA-N Asp-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O CSEJMKNZDCJYGJ-XHNCKOQMSA-N 0.000 description 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100291031 Caenorhabditis elegans gly-13 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- DCXGXDGGXVZVMY-GHCJXIJMSA-N Cys-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CS DCXGXDGGXVZVMY-GHCJXIJMSA-N 0.000 description 1
- HKALUUKHYNEDRS-GUBZILKMSA-N Cys-Leu-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HKALUUKHYNEDRS-GUBZILKMSA-N 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000016169 Fish-eye disease Diseases 0.000 description 1
- KZKBJEUWNMQTLV-XDTLVQLUSA-N Gln-Ala-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZKBJEUWNMQTLV-XDTLVQLUSA-N 0.000 description 1
- KDXKFBSNIJYNNR-YVNDNENWSA-N Gln-Glu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDXKFBSNIJYNNR-YVNDNENWSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 description 1
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 1
- UEILCTONAMOGBR-RWRJDSDZSA-N Gln-Thr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UEILCTONAMOGBR-RWRJDSDZSA-N 0.000 description 1
- WOSRKEJQESVHGA-CIUDSAMLSA-N Glu-Arg-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O WOSRKEJQESVHGA-CIUDSAMLSA-N 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 1
- XMPAXPSENRSOSV-RYUDHWBXSA-N Glu-Gly-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XMPAXPSENRSOSV-RYUDHWBXSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- QIQABBIDHGQXGA-ZPFDUUQYSA-N Glu-Ile-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QIQABBIDHGQXGA-ZPFDUUQYSA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- PMSMKNYRZCKVMC-DRZSPHRISA-N Glu-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)O)N PMSMKNYRZCKVMC-DRZSPHRISA-N 0.000 description 1
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 1
- SYAYROHMAIHWFB-KBIXCLLPSA-N Glu-Ser-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYAYROHMAIHWFB-KBIXCLLPSA-N 0.000 description 1
- DLISPGXMKZTWQG-IFFSRLJSSA-N Glu-Thr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O DLISPGXMKZTWQG-IFFSRLJSSA-N 0.000 description 1
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 1
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 1
- QRWPTXLWHHTOCO-DZKIICNBSA-N Glu-Val-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QRWPTXLWHHTOCO-DZKIICNBSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- WSWWTQYHFCBKBT-DVJZZOLTSA-N Gly-Thr-Trp Chemical compound C[C@@H](O)[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O WSWWTQYHFCBKBT-DVJZZOLTSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- SYMSVYVUSPSAAO-IHRRRGAJSA-N His-Arg-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O SYMSVYVUSPSAAO-IHRRRGAJSA-N 0.000 description 1
- KYMUEAZVLPRVAE-GUBZILKMSA-N His-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KYMUEAZVLPRVAE-GUBZILKMSA-N 0.000 description 1
- BDHUXUFYNUOUIT-SRVKXCTJSA-N His-Asp-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BDHUXUFYNUOUIT-SRVKXCTJSA-N 0.000 description 1
- VTZYMXGGXOFBMX-DJFWLOJKSA-N His-Ile-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O VTZYMXGGXOFBMX-DJFWLOJKSA-N 0.000 description 1
- 101001027052 Homo sapiens Thymidylate kinase Proteins 0.000 description 1
- SACHLUOUHCVIKI-GMOBBJLQSA-N Ile-Arg-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SACHLUOUHCVIKI-GMOBBJLQSA-N 0.000 description 1
- NULSANWBUWLTKN-NAKRPEOUSA-N Ile-Arg-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N NULSANWBUWLTKN-NAKRPEOUSA-N 0.000 description 1
- SCHZQZPYHBWYEQ-PEFMBERDSA-N Ile-Asn-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SCHZQZPYHBWYEQ-PEFMBERDSA-N 0.000 description 1
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 1
- HOLOYAZCIHDQNS-YVNDNENWSA-N Ile-Gln-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HOLOYAZCIHDQNS-YVNDNENWSA-N 0.000 description 1
- MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 1
- KFVUBLZRFSVDGO-BYULHYEWSA-N Ile-Gly-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O KFVUBLZRFSVDGO-BYULHYEWSA-N 0.000 description 1
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 1
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 1
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 1
- FFJQAEYLAQMGDL-MGHWNKPDSA-N Ile-Lys-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FFJQAEYLAQMGDL-MGHWNKPDSA-N 0.000 description 1
- BKPPWVSPSIUXHZ-OSUNSFLBSA-N Ile-Met-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N BKPPWVSPSIUXHZ-OSUNSFLBSA-N 0.000 description 1
- GVEODXUBBFDBPW-MGHWNKPDSA-N Ile-Tyr-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 GVEODXUBBFDBPW-MGHWNKPDSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- GBDMISNMNXVTNV-XIRDDKMYSA-N Leu-Asp-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GBDMISNMNXVTNV-XIRDDKMYSA-N 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 1
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 1
- KUIDCYNIEJBZBU-AJNGGQMLSA-N Leu-Ile-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O KUIDCYNIEJBZBU-AJNGGQMLSA-N 0.000 description 1
- TVEOVCYCYGKVPP-HSCHXYMDSA-N Leu-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N TVEOVCYCYGKVPP-HSCHXYMDSA-N 0.000 description 1
- MJTOYIHCKVQICL-ULQDDVLXSA-N Leu-Met-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N MJTOYIHCKVQICL-ULQDDVLXSA-N 0.000 description 1
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 1
- AXVIGSRGTMNSJU-YESZJQIVSA-N Leu-Tyr-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N AXVIGSRGTMNSJU-YESZJQIVSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- DGWXCIORNLWGGG-CIUDSAMLSA-N Lys-Asn-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O DGWXCIORNLWGGG-CIUDSAMLSA-N 0.000 description 1
- HEWWNLVEWBJBKA-WDCWCFNPSA-N Lys-Gln-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN HEWWNLVEWBJBKA-WDCWCFNPSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- ONPDTSFZAIWMDI-AVGNSLFASA-N Lys-Leu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ONPDTSFZAIWMDI-AVGNSLFASA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- PIXVFCBYEGPZPA-JYJNAYRXSA-N Lys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N PIXVFCBYEGPZPA-JYJNAYRXSA-N 0.000 description 1
- AEIIJFBQVGYVEV-YESZJQIVSA-N Lys-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)N)C(=O)O AEIIJFBQVGYVEV-YESZJQIVSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- IMDJSVBFQKDDEQ-MGHWNKPDSA-N Lys-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)N IMDJSVBFQKDDEQ-MGHWNKPDSA-N 0.000 description 1
- RPWQJSBMXJSCPD-XUXIUFHCSA-N Lys-Val-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(O)=O RPWQJSBMXJSCPD-XUXIUFHCSA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- AHZNUGRZHMZGFL-GUBZILKMSA-N Met-Arg-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCNC(N)=N AHZNUGRZHMZGFL-GUBZILKMSA-N 0.000 description 1
- SQUTUWHAAWJYES-GUBZILKMSA-N Met-Asp-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SQUTUWHAAWJYES-GUBZILKMSA-N 0.000 description 1
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 1
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 1
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 1
- JOYFULUKJRJCSX-IUCAKERBSA-N Met-Met-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O JOYFULUKJRJCSX-IUCAKERBSA-N 0.000 description 1
- JACMWNXOOUYXCD-JYJNAYRXSA-N Met-Val-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JACMWNXOOUYXCD-JYJNAYRXSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- BRDYYVQTEJVRQT-HRCADAONSA-N Phe-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BRDYYVQTEJVRQT-HRCADAONSA-N 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- DJPXNKUDJKGQEE-BZSNNMDCSA-N Phe-Asp-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DJPXNKUDJKGQEE-BZSNNMDCSA-N 0.000 description 1
- KAGCQPSEVAETCA-JYJNAYRXSA-N Phe-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N KAGCQPSEVAETCA-JYJNAYRXSA-N 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- ISYSEOWLRQKQEQ-JYJNAYRXSA-N Phe-His-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISYSEOWLRQKQEQ-JYJNAYRXSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- FUAIIFPQELBNJF-ULQDDVLXSA-N Phe-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FUAIIFPQELBNJF-ULQDDVLXSA-N 0.000 description 1
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- WECYCNFPGZLOOU-FXQIFTODSA-N Pro-Asn-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O WECYCNFPGZLOOU-FXQIFTODSA-N 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
- VAIZFHMTBFYJIA-ACZMJKKPSA-N Ser-Asp-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O VAIZFHMTBFYJIA-ACZMJKKPSA-N 0.000 description 1
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- MQBTXMPQNCGSSZ-OSUNSFLBSA-N Thr-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N MQBTXMPQNCGSSZ-OSUNSFLBSA-N 0.000 description 1
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 1
- WLDUCKSCDRIVLJ-NUMRIWBASA-N Thr-Gln-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O WLDUCKSCDRIVLJ-NUMRIWBASA-N 0.000 description 1
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- XYFISNXATOERFZ-OSUNSFLBSA-N Thr-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XYFISNXATOERFZ-OSUNSFLBSA-N 0.000 description 1
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 1
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 1
- MFMGPEKYBXFIRF-SUSMZKCASA-N Thr-Thr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFMGPEKYBXFIRF-SUSMZKCASA-N 0.000 description 1
- ILUOMMDDGREELW-OSUNSFLBSA-N Thr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O ILUOMMDDGREELW-OSUNSFLBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 229940123623 Thymidylate kinase inhibitor Drugs 0.000 description 1
- WCTYCXZYBNKEIV-SXNHZJKMSA-N Trp-Glu-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)=CNC2=C1 WCTYCXZYBNKEIV-SXNHZJKMSA-N 0.000 description 1
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 1
- DMWNPLOERDAHSY-MEYUZBJRSA-N Tyr-Leu-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DMWNPLOERDAHSY-MEYUZBJRSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- AGXGCFSECFQMKB-NHCYSSNCSA-N Val-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N AGXGCFSECFQMKB-NHCYSSNCSA-N 0.000 description 1
- BMOFUVHDBROBSE-DCAQKATOSA-N Val-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N BMOFUVHDBROBSE-DCAQKATOSA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- OIFWQOKDSPDILA-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 OIFWQOKDSPDILA-XLPZGREQSA-N 0.000 description 1
- JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000005515 capillary zone electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010088076 lactate dehydrogenase 2 Proteins 0.000 description 1
- HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000034932 regulation of DNA biosynthetic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108700004896 tripeptide FEG Proteins 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
An unliganded form of Staphylococcus aureus thymidylate kinase (S. aureus TMK) has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 .ANG. resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus TMK activity.
Description
CRYSTALLIZATION AND STRUCTURE DETERMINATION OF
STAPHYLOCOCCUS A UREUS THYMIDYLATE KINASE
This application claims the benefit of U.S. Provisional Application Serial No. 60/147,117, filed 4 August 1999, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
This invention relates to the crystallization and structure determination of thymidylate kinase (TMK) from Staphylococcus aureus.
BACKGROUND
Thymidylate kinase (TMK) catalyzes the synthesis of (deoxy)thymidine diphosphate (dTDP) from (deoxy)thymidine monophosphate (dTMP) and ATP along the pathway leading to the synthesis of (deoxy)thymidine triphosphate (dTTP) necessary for DNA
synthesis (Figure 1). Since the phosphorylation of dTDP to dTTP is conducted by a nonspecific diphosphate kinase, TMK is a key player in the regulation of DNA synthesis and is a potential antibacterial target. Interest in thymidylate kinase biochemistry increased when it was recently discovered that this enzyme serves as one of the activators for the AIDS
drug, 3'-azido-3'-deoxythymidine (AZT) (L.W. Frick et al., Biochem.
Biophys. Res. Comm. 154:124-9 (1988); A. Fridland et al., Mol. Pharmacol.
37:665-70 (1990)). Activation of AZT to azidothymidine triphosphate (AZT-TP) proceeds along cellular phosphorylation pathways to produce the species which is incorporated into growing DNA chains by HIV reverse transcriptase. Similar to its role in serving as a control point for the production of dTTP, thymidylate kinase catalyzes the rate limiting phosphorylation of AZT-monophosphate to AZT-diphosphate (AZT-DP) AZT-DP phosphorylation to AZT-TP is then catalyzed by a nonspecific diphosphate kinase.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex that includes preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S.
aureus thymidylate kinase from a solution including about 5 wt. % to about S0 wt. % PEG (preferably having a number average molecular weight between about 200 and about 20,000), about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. In another aspect, the present invention provides a method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex that includes preparing purified S.
aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S. aureus thymidylate kinase from a solution including about 2 mM to about 20 mM (3,y-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7 In another aspect, the present invention provides crystalline forms of an S. aureus thymidylate kinase molecule. In one embodiment, a crystal of S. aureus thymidylate kinase is provided having the trigonal space group symmetry P21.
In another aspect, the present invention provides a scalable three dimensional configuration of points derived from structure coordinates of at least a portion of an S. aureus thymidylate kinase molecule or molecular complex. In one embodiment, the scalable three dimensional set of points is derived from structure coordinates of at least the backbone atoms of the amino acids representing a TMP and/or TMP/ATP substrate binding pocket of an S. aureus thymidylate kinase molecule or molecular complex. In another embodiment, the scalable three dimensional configuration of points is derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex. On a molecular scale, the configuration of points derived from a homologous molecule or molecular complex have a root mean square deviation of less than about 2.1 ~ from the structure coordinates of the molecule or complex In another aspect, the present invention provides a molecule or molecular complex that includes at least a portion of an S. aureus thymidylate kinase TMP and/or TMP/ATP substrate binding pocket. In one embodiment, the S. aureus thymidylate kinase TMP substrate binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 fir, preferably less than about 1.5 A, more preferably less than about 1.0 ~, and most preferably less than about 0.5 t~ from points representing the backbone atoms of the amino acids. In another embodiment, the S. aureus thymidylate kinase TMP/ATP substrate binding pocket includes the amino acids listed in Table 4, preferably the amino acids listed in Table 5, and more preferably the amino acids listed in Table 6, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 ~, preferably less than about 1.5 ~, more preferably less than about 1.0 ~, and most preferably less than about 0.5 ~ from points representing the backbone atoms of the amino acids.
Table 1 Residues within about 4~ of the TMP binding pocket of S. aureus TMK
STAPHYLOCOCCUS A UREUS THYMIDYLATE KINASE
This application claims the benefit of U.S. Provisional Application Serial No. 60/147,117, filed 4 August 1999, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
This invention relates to the crystallization and structure determination of thymidylate kinase (TMK) from Staphylococcus aureus.
BACKGROUND
Thymidylate kinase (TMK) catalyzes the synthesis of (deoxy)thymidine diphosphate (dTDP) from (deoxy)thymidine monophosphate (dTMP) and ATP along the pathway leading to the synthesis of (deoxy)thymidine triphosphate (dTTP) necessary for DNA
synthesis (Figure 1). Since the phosphorylation of dTDP to dTTP is conducted by a nonspecific diphosphate kinase, TMK is a key player in the regulation of DNA synthesis and is a potential antibacterial target. Interest in thymidylate kinase biochemistry increased when it was recently discovered that this enzyme serves as one of the activators for the AIDS
drug, 3'-azido-3'-deoxythymidine (AZT) (L.W. Frick et al., Biochem.
Biophys. Res. Comm. 154:124-9 (1988); A. Fridland et al., Mol. Pharmacol.
37:665-70 (1990)). Activation of AZT to azidothymidine triphosphate (AZT-TP) proceeds along cellular phosphorylation pathways to produce the species which is incorporated into growing DNA chains by HIV reverse transcriptase. Similar to its role in serving as a control point for the production of dTTP, thymidylate kinase catalyzes the rate limiting phosphorylation of AZT-monophosphate to AZT-diphosphate (AZT-DP) AZT-DP phosphorylation to AZT-TP is then catalyzed by a nonspecific diphosphate kinase.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex that includes preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S.
aureus thymidylate kinase from a solution including about 5 wt. % to about S0 wt. % PEG (preferably having a number average molecular weight between about 200 and about 20,000), about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. In another aspect, the present invention provides a method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex that includes preparing purified S.
aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S. aureus thymidylate kinase from a solution including about 2 mM to about 20 mM (3,y-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7 In another aspect, the present invention provides crystalline forms of an S. aureus thymidylate kinase molecule. In one embodiment, a crystal of S. aureus thymidylate kinase is provided having the trigonal space group symmetry P21.
In another aspect, the present invention provides a scalable three dimensional configuration of points derived from structure coordinates of at least a portion of an S. aureus thymidylate kinase molecule or molecular complex. In one embodiment, the scalable three dimensional set of points is derived from structure coordinates of at least the backbone atoms of the amino acids representing a TMP and/or TMP/ATP substrate binding pocket of an S. aureus thymidylate kinase molecule or molecular complex. In another embodiment, the scalable three dimensional configuration of points is derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex. On a molecular scale, the configuration of points derived from a homologous molecule or molecular complex have a root mean square deviation of less than about 2.1 ~ from the structure coordinates of the molecule or complex In another aspect, the present invention provides a molecule or molecular complex that includes at least a portion of an S. aureus thymidylate kinase TMP and/or TMP/ATP substrate binding pocket. In one embodiment, the S. aureus thymidylate kinase TMP substrate binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 fir, preferably less than about 1.5 A, more preferably less than about 1.0 ~, and most preferably less than about 0.5 t~ from points representing the backbone atoms of the amino acids. In another embodiment, the S. aureus thymidylate kinase TMP/ATP substrate binding pocket includes the amino acids listed in Table 4, preferably the amino acids listed in Table 5, and more preferably the amino acids listed in Table 6, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 ~, preferably less than about 1.5 ~, more preferably less than about 1.0 ~, and most preferably less than about 0.5 ~ from points representing the backbone atoms of the amino acids.
Table 1 Residues within about 4~ of the TMP binding pocket of S. aureus TMK
Table 2 Residues within about 7~ of the TMP binding pocket of S. aureus TMK
ILE 51 ARG 93 ~ TYR 168 Table 3 Residues within about 10~ of the TMP binding pocket of S aureus TMK
ILE 51 ARG 93 ~ TYR 168 Table 3 Residues within about 10~ of the TMP binding pocket of S aureus TMK
Table 4 Residues within about 4~ of the TMP/ATP binding pocket of S. aureus TMK
Table 5 Residues within about 7~ of the TMP/ATP binding pocket of S. aureus TMK
GLY 13 ALA 68 LEU ~ 132 Table 6 Residues within about 10~ of the TMP/ATP binding pocket of S. aureus TMK
GLU 63 ILE 108 ~ VAL 192 In another aspect, the present invention provides molecules or molecular complexes that are structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex.
In another aspect, the present invention provides a machine readable storage medium including the structure coordinates of all or a portion of an S. aureus thymidylate kinase molecule, molecular complex, a structurally homologous molecule or complex, including structurally equivalent structures, as defined herein, particularly a substrate binding pocket thereof, or a similarly shaped homologous substrate binding pocket.
Table 5 Residues within about 7~ of the TMP/ATP binding pocket of S. aureus TMK
GLY 13 ALA 68 LEU ~ 132 Table 6 Residues within about 10~ of the TMP/ATP binding pocket of S. aureus TMK
GLU 63 ILE 108 ~ VAL 192 In another aspect, the present invention provides molecules or molecular complexes that are structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex.
In another aspect, the present invention provides a machine readable storage medium including the structure coordinates of all or a portion of an S. aureus thymidylate kinase molecule, molecular complex, a structurally homologous molecule or complex, including structurally equivalent structures, as defined herein, particularly a substrate binding pocket thereof, or a similarly shaped homologous substrate binding pocket.
A storage medium encoded with these data is capable of displaying on a computer screen, or similar viewing device, a three-dimensional graphical representation of a molecule or molecular complex which comprises a substrate binding pocket or a similarly shaped homologous substrate binding pocket.
In another aspect, the present invention provides a method for identifying inhibitors, ligands, and the like for an S. aureus thymidylate kinase molecule by providing the coordinates of a molecule of S aureus thymidylate kinase to a computerized modeling system; identifying chemical entities that are likely to bind to or interfere with the molecule (e.g., screening a small molecule library); and, optionally, procuring or synthesizing and assaying the compounds or analogues derived therefrom for bioactivity. In another aspect, the present invention provides methods for designing inhibitors, ligands, and the like by providing the coordinates of a molecule of S. aureus thymidylate kinase to a computerized modeling system; designing a chemical entity that is likely to bind to or interfere with the molecule; and optionally synthesizing the chemical entity and assaying the chemical entity for bioactivity. In another aspect, the present invention provides inhibitors and ligands designed or identified by the above methods.
In one embodiment, a composition is provided that includes an inhibitor or ligand designed or identified by the above method. In another embodiment, the composition is a pharmaceutical composition.
In another aspect, the present invention provides a method involving molecular replacement to obtain structural information about a molecule or molecular complex of unknown structure. The method includes crystallizing the molecule or molecular complex, generating an x-ray diffraction pattern from the crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates set forth in Fig. 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
In another aspect, the present invention provides a method for homology modeling an S. aureus thymidylate kinase homolog.
In another aspect, the present invention provides a method for identifying inhibitors, ligands, and the like for an S. aureus thymidylate kinase molecule by providing the coordinates of a molecule of S aureus thymidylate kinase to a computerized modeling system; identifying chemical entities that are likely to bind to or interfere with the molecule (e.g., screening a small molecule library); and, optionally, procuring or synthesizing and assaying the compounds or analogues derived therefrom for bioactivity. In another aspect, the present invention provides methods for designing inhibitors, ligands, and the like by providing the coordinates of a molecule of S. aureus thymidylate kinase to a computerized modeling system; designing a chemical entity that is likely to bind to or interfere with the molecule; and optionally synthesizing the chemical entity and assaying the chemical entity for bioactivity. In another aspect, the present invention provides inhibitors and ligands designed or identified by the above methods.
In one embodiment, a composition is provided that includes an inhibitor or ligand designed or identified by the above method. In another embodiment, the composition is a pharmaceutical composition.
In another aspect, the present invention provides a method involving molecular replacement to obtain structural information about a molecule or molecular complex of unknown structure. The method includes crystallizing the molecule or molecular complex, generating an x-ray diffraction pattern from the crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates set forth in Fig. 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
In another aspect, the present invention provides a method for homology modeling an S. aureus thymidylate kinase homolog.
DEFINITIONS
Two crystallographic data sets (with structure factors F) are considered isomorphous if, after scaling, 0 F ~ I F 1-F2 F ~ F1 is less than about 35% for the reflections between 8 ~ and 4 ~.
ABBREVIATIONS
The following abbreviations are used throughout this disclosure:
Staphylococcus aureus (S. aureus).
Thymidylate kinase (T. kinase or TMK).
Thymidine 5'-monophosphate (TMP).
Thymidine 5'-diphosphate (TDP).
Thymidine 5'-triphosphate (TTP).
Phospho(enol)pyruvate (PEP) Reduced nicotinamide adenine dinucleotide (NADH) Oxidized nicotinamide adenine dinucleotide (NAD~
Pyruvate kinase (PK) Lactate dehydrogenase (LDH) Nucleoside-5'-diphosphate kinase (NDP-Kinase) (Deoxy)thymidine monophosphate (dTMP).
(Deoxy)thymidine diphosphate (dTDP).
(Deoxy)thymidine triphosphate (dTTP).
Adenosine 5'-diphosphate (ADP).
Adenosine 5'-triphosphate (ATP).
Isopropylthio-(3-D-galactoside (IPTG).
Dithiothreitol (DTT).
Two crystallographic data sets (with structure factors F) are considered isomorphous if, after scaling, 0 F ~ I F 1-F2 F ~ F1 is less than about 35% for the reflections between 8 ~ and 4 ~.
ABBREVIATIONS
The following abbreviations are used throughout this disclosure:
Staphylococcus aureus (S. aureus).
Thymidylate kinase (T. kinase or TMK).
Thymidine 5'-monophosphate (TMP).
Thymidine 5'-diphosphate (TDP).
Thymidine 5'-triphosphate (TTP).
Phospho(enol)pyruvate (PEP) Reduced nicotinamide adenine dinucleotide (NADH) Oxidized nicotinamide adenine dinucleotide (NAD~
Pyruvate kinase (PK) Lactate dehydrogenase (LDH) Nucleoside-5'-diphosphate kinase (NDP-Kinase) (Deoxy)thymidine monophosphate (dTMP).
(Deoxy)thymidine diphosphate (dTDP).
(Deoxy)thymidine triphosphate (dTTP).
Adenosine 5'-diphosphate (ADP).
Adenosine 5'-triphosphate (ATP).
Isopropylthio-(3-D-galactoside (IPTG).
Dithiothreitol (DTT).
Dimethyl sulfoxide (DMSO).
Polyethylene glycol (PEG).
Multiple anomalous dispersion (MAD).
The following amino acid abbreviations are used throughout this disclosure:
A = Ala = Alanine I T = Thr = Threonine V = Val = Valine ~ C = Cys = Cysteine L = Leu = Leucine ~ Y = Tyr = Tyrosine I = Ile = Isoleucine ~ N = Asn = Asparagine P = Pro = Proline ~ Q = Gln = Glutamine F = Phe = Phenylalanine ~ D = Asp = Aspartic Acid W = Trp = Tryptophan ~ E = Glu = Glutamic Acid M = Met = Methionine ~ K = Lys = Lysine G = Gly = Glycine ~ R = Arg = Arginine S = Ser = Serine ~ H = His = Histidine BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the biosynthetic pathway for the synthesis of thymidylate. The reaction catalyzed by thymidylate kinase is boxed.
Figure 2 lists the atomic structure coordinates for recombinant S. aureus thymidylate kinase (with a His6 tag) as derived by x-ray diffraction from a crystal of that complex. The following abbreviations are used in Figure 2:
"Atom" refers to the element whose coordinates are measured. The second column defines the number of the atom in the structure. T'he letters in the third column define the element. The fourth and fifth columns define the amino acid and the number of the amino acid in the structure, respectively.
Polyethylene glycol (PEG).
Multiple anomalous dispersion (MAD).
The following amino acid abbreviations are used throughout this disclosure:
A = Ala = Alanine I T = Thr = Threonine V = Val = Valine ~ C = Cys = Cysteine L = Leu = Leucine ~ Y = Tyr = Tyrosine I = Ile = Isoleucine ~ N = Asn = Asparagine P = Pro = Proline ~ Q = Gln = Glutamine F = Phe = Phenylalanine ~ D = Asp = Aspartic Acid W = Trp = Tryptophan ~ E = Glu = Glutamic Acid M = Met = Methionine ~ K = Lys = Lysine G = Gly = Glycine ~ R = Arg = Arginine S = Ser = Serine ~ H = His = Histidine BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the biosynthetic pathway for the synthesis of thymidylate. The reaction catalyzed by thymidylate kinase is boxed.
Figure 2 lists the atomic structure coordinates for recombinant S. aureus thymidylate kinase (with a His6 tag) as derived by x-ray diffraction from a crystal of that complex. The following abbreviations are used in Figure 2:
"Atom" refers to the element whose coordinates are measured. The second column defines the number of the atom in the structure. T'he letters in the third column define the element. The fourth and fifth columns define the amino acid and the number of the amino acid in the structure, respectively.
"X, Y, Z" crystallographically define the atomic position of the element measured.
"Occ" is an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of "1" indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.
"B" is a thermal factor that measures movement of the atom around its atomic center.
Figure 3 depicts S aureus thymidylate kinase using (a) a ribbon diagram showing the backbone structure of the enzyme and (b) a schematic diagram showing the secondary structure for a TMK monomer Disordered loops are indicated by arrows.
Figure 4 depicts a structural comparison of E. coli TMK +
APST and S. aureus TMK. The overall fold of the two proteins is well-conserved, but note that the lid in the E. coli TMK is not present in the S.
aureus TMK due to the absence of a ligand.
Figure 5 depicts (a) a stereo view of a superposition of S.
aureus thymidylate kinase and E. coli thymidylate kinase and (b) the amino acid sequence alignment of S. aureus thymidylate kinase (SEQ ID NO:1) (capital letters, upper sequence) and E. coli thymidylate kinase (SEQ ID
N0:2) (lower sequence). Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicated by ~ and similar residues are indicated by . and : symbols.
Figure 6 depicts (a) a stereo view of a superposition of S.
aureus thymidylate kinase and S. cerevisiae thymidylate kinase and (b) the sequence alignment of S. aureus thyrnidylate kinase (SEQ ID NO:1 ) (capital letters, upper sequence) and S cerevisiae thymidylate kinase (SEQ ID
N0:3) (lower sequence). Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicated by ~ and similar residues are indicated by . and : symbols.
Figure 7 depicts a) a substrate-based inhibitor (APST) for thymidylate kinase with a Kd of 20 nM for E. coli TMK (A. Lavie et al., Biochemistry 37:3677-86 (1998); A. Lavie et al., Proc. Natl. Acad. Sci.
USA, 95:14045-50 (1998)). b) protein ligand interactions for E. coli TMK
(shaded boxes, from A. Lavie et al., Proc. Natl. Acad. Sci. USA, 95:14045-50 (1998)) with the corresponding residues from S. aureus TMK underlined (conservative mutations are marked with an asterisk). Active site residues from the S. cerevisiae are boxed (where no corresponding residue from E.
coli TMK is present, an arrow indicates the point of contact with the substrate).
Figure 8 depicts the anomalous difference Patterson maps at (a) 2.7 A and (b) at 2.3 ~ resolution.
Figure 9 depicts electron density maps of residues 76 to 82 from molecule 1 of S. aureus thymidylate kinase (SEQ ID NO:1) at (a) 2.7 ~ and (b) at 2.3 ~ resolution.
Figure 10 lists the structure factors and multiple anomalous dispersion phases for the crystal structure of S aureus thymidylate kinase (SEQ ID NO:1). "INDE" refers to the indices h, k, and 1 (columns 2, 3, and 4 respectively) of the lattice planes. "FOBS" refers to the structure factor (F) of the observed reflections. "SIGMA" is the standard deviation for the observations. "PHAS" refers to the phase used for the observations. "FOM"
refers to the figure of merit.
Figure 11 depicts a surface representation of a) E. coli TMK
with the inhibitor APST and b) S. aureus TMK with a hypothetical positioning of APST based on a structural alignment of Ca atoms from the E.
coli TMK + APST structure.
DETAILED DESCRIPTION OF THE INVENTION
Crystalline Forms) and Method of Making The three-dimensional structure of S. aureus thymidylate kinase was solved using high resolution x-ray crystallography to 2.3 ~
resolution (see Figure 2 and Example 1). Accordingly, the invention includes a TMK crystal and/or a crystal with TMK co-crystallized with a ligand, such as an inhibitor. Preferably, the crystal has trigonal space group symmetry P2~. More preferably, the crystal comprises rectangular shaped unit cells, each unit cell having dimensions of a, b, and c; wherein a is about 40 ~ to about 60 ~, b is about 80 ~ to about 100 ~, and c is about 40 ~ to about 60 ~; and wherein a = y = 90° and (3 is about 80° to about 120°. The crystallized enzyme is a dimer with a single dimer in the asymmetric unit.
Purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml may be crystallized, for example, by using a streak seeding procedure from a solution including about 5 wt. % to about 50 wt. % PEG (preferably having a number average molecular weight between about 200 and about 20,000), about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. Use of a buffer having a pKa of between about 5 and 8 is preferred. Molecular complexes of purified S.
aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml may also be crystallized, for example, from a solution including about 2 mM to about 20 mM (3,y-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. A "molecular complex" means a protein in covalent or non-covalent association with a chemical entity. A buffer having a pKa of between about 5 and 8 is preferred for use in the crystallization method. A particularly preferred buffer is about 0.4M to about 2.0M sodium citrate. Variation in buffer and buffer pH as well as other additives such as PEG is apparent to those skilled in the art and may result in similar crystals.
The invention further includes an S. aureus thymidylate kinase crystal or S. aureus thymidylate kinase/ligand crystal that is isomorphous with an S. aureus thymidylate kinase crystal characterized by a unit cell having dimensions of a, b, and c; wherein a is about 40 t~ to about 60 fir, b is about 80 ~ to about 100 ~, and c is about 40 ~r to about 60 ~;
and wherein a = y = 90° and ~i is about 80° to about 120°.
X-ray C s~~tallo~raphic Analysis Each of the constituent amino acids of S. aureus thymidylate kinase is defined by a set of structure coordinates as set forth in Figure 2.
The term "structure coordinates" refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of an S.
aureus thymidylate kinase complex in crystal form. The diffraction data are used to calculate an electron density map of the repeating unit of the crystal.
The electron density maps are then used to establish the positions of the individual atoms of the S. aureus thymidylate kinase protein or protein/ligand complex.
Slight variations in structure coordinates can be generated by mathematically manipulating the S. aureus thymidylate kinase or S. aureus thymidylate kinase/ligand structure coordinates. For example, the structure coordinates set forth in Figure 2 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above. Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal, could also yield variations in structure coordinates. Such slight variations in the individual coordinates will have little effect on overall shape. If such variations are within an acceptable standard error as compared to the original coordinates, the resulting three-dimensional shape is considered to be structurally equivalent.
Structural equivalence is described in more detail below.
It should be noted that slight variations in individual structure coordinates of the S aureus thymidylate kinase would not be expected to significantly alter the nature of chemical entities such as ligands that could associate with the substrate binding pockets. In this context, the phrase "associating with" refers to a condition of proximity between a chemical entity, or portions thereof, and an S. aureus thymidylate kinase molecule or portions thereof. The association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent.
Thus, for example, a ligand that bound to a substrate binding pocket of S. aureus thymidylate kinase would also be expected to bind to or interfere with another substrate binding pocket whose structure coordinates define a shape that falls within the acceptable error.
It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus thymidylate kinase may be different than that of S aureus thymidylate kinase expressed in E.
coli.
Active Site and Other Structural Features Applicants' invention has provided, for the first time, information about the shape and structure of the substrate binding pockets of S. aureus thymidylate kinase. The structures of both the TMP and the TMP/ATP substrate binding pockets are elucidated. The secondary structure of the S. aureus thymidylate kinase monomer includes a five stranded parallel ~i sheet surrounded by nine a helices (Figure 3). This solved crystal structure of S. aureus thymidylate kinase does not contain any ligand which has resulted in a disordered loop between helices a7 and a8 (Figure 4). This loop has been called the "lid" in the structures of thymidylate kinase homologs from E. coli and S. cerevisiae. In E. coli the lid contains Arg 153 which is responsible for phosphate binding of the ATP
substrate as shown in the X-ray crystal structure of the E. coli enzyme with the APST inhibitor, a transition state analog of TMP/ATP (A. Lavie et al., Biochemistry 37:3677-86 (1998)). In contrast the analogous arginine in S.
cerevisiae comes from the P loop (Arg 15) between ail and al (A. Lavie et al., Proc. Natl. Acad. Sci. USA, 95:14045-SO (1998)). This distinction as further manifested in sequence differences between the P loop and lid regions has led to the classification of the S. cerevisiae enzyme as a class I
thymidylate kinase (which also includes human thymidylate kinase) and the E. coli enzyme as a class II thymidylate kinase (A. Lavie, Proc. Natl. Acad.
Sci. USA, 95:14045-50 (1998)). Fortunately, S. aureus (SEQ ID NO:1) has greater sequence similarity to the E. coli enzyme (SEQ ID N0:2, 38%
identical, 59% similar) than the S. cerevisiae enzyme (SEQ ID N0:3, 28%
identical, 46% similar) and contains 8148 in the lid region suggesting it should be classified as a class II thymidylate kinase (Figures S and 6). This classification suggests that it might be possible to design inhibitors that are specific for the S. aureus enzyme and not eukaryotic thymidylate kinases.
Superposition of the S aureus TMK with E. coli TMK gave a r.m.s. deviation of 2.19 ~ for analogous residues (Figure 5). Similarly, superposition of S. aureus TMK with S cerevisiae TMK gave a r.m.s.
deviation of 3.26 ~ (Figure 6). Analysis of the active site residues from E.
coli TMK as observed in the APST inhibitor complex shows at least eleven residues that make direct hydrogen bonds to the inhibitor and another six residues make water mediated or hydrophobic interactions. Analysis of the active site residues from S. aureus TMK sequence reveals strong conservation of these active site residues with the E. coli active site (Figure 7b); 15 of the 17 residues involved in the protein-inhibitor complex are identical while the two remaining residues are strongly conserved. An analogous comparison for the S. cerevisiae TMK (Figure 7b) shows only four of 18 residues conserved within the active site suggesting that specificity between the S. aureus and eukaryotic thymidylate kinases might be attainable.
Comparing the liganded E. coli TMK structure with the unliganded S. aureus structure, it is apparent that a significant movement of the main chain around the active site (e.g. helix a2 and helix a7) including the ordering of the disordered residues must occur upon ligand binding.
Figure 11 shows where the APST inhibitor would be expected in the S.
aureus TMK structure based on an alignment of the E. coli TMK-APST
inhibitor complex. There does appear to be a surface in the S. aureus TMK
structure which would complement the ATP and TMP substrates, although it is clear from this surface view that an important part of the structure, the lid, is missing from the S. aureus TMK structure. Figure 8 clearly illustrates the role for this portion of the protein in completing the active site and closing off the thymidylate moiety from solvent.
Binding pockets are of significant utility in fields such as drug discovery. The association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the binding pockets of receptors and enzymes. Such associations may occur with all or any parts of the binding pocket. An understanding of such associations helps lead to the design of drugs having more favorable associations with their target, and thus improved biological effects. Therefore, this information is valuable in designing potential inhibitors of S. aureus thymidylate kinase-like substrate binding pockets, as discussed in more detail below.
The term "binding pocket," as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity. Thus, a binding pocket may include or consist of features such as cavities, surfaces, or interfaces between domains. Chemical entities that may associate with a binding pocket include, but are not limited to, cofactors, substrates, inhibitors, agonists, and antagonists.
The amino acid constituents of an S. aureus thymidylate kinase substrate binding pocket as defined herein are positioned in three dimensions in accordance with the structure coordinates listed in Figure 2.
In one aspect, the structure coordinates defining a substrate binding pocket of S. aureus thymidylate kinase include structure coordinates of all atoms in the constituent amino acids; in another aspect, the structure coordinates of a substrate binding pocket include structure coordinates of just the backbone atoms of the constituent atoms.
The TMP substrate binding pocket of S. aureus thymidylate kinase preferably includes the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3, as represented by the structure coordinates listed in Figure 2.
Alternatively, the TMP substrate binding pocket of S. aureus thymidylate kinase may be defined by those amino acids whose backbone atoms are situated within about 3.5 t~, more preferably within about 5 ~, most preferably within about 7 A, of one or more constituent atoms of a bound substrate or inhibitor. In yet another alternative, the TMP substrate binding pocket may be defined by those amino acids whose backbone atoms are, situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Ser98, the sphere having a radius of about 10 ~, preferably about 15 ~, and more preferably about 20 ~.
The TMP/ATP substrate binding pocket of S. aureus thymidylate kinase preferably includes the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6, as represented by the structure coordinates listed in Figure 2. Alternatively, the TMP/ATP substrate binding pocket of S. aureus thyrnidylate kinase may be defined by those amino acids whose backbone atoms are situated within about 3.5 ~, more preferably within about 5 ~, most preferably within about 7 ~, of one or more constituent atoms of a bound substrate or inhibitor. In yet another alternative, the TMP/ATP substrate binding pocket may be defined by those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Arg93, the sphere having a radius of about 10 t~, preferably about 15 ~, and more preferably about 20 ~.
The term "S. aureus thymidylate kinase-like substrate binding pocket" refers to a portion of a molecule or molecular complex whose shape is sufficiently similar to at least a portion of a substrate binding pocket of S
aureus thymidylate kinase as to be expected to bind related TMP and/or ATP structural analogues. A structurally equivalent substrate binding pocket is defined by a root mean square deviation from the structure coordinates of the backbone atoms of the amino acids that make up substrate binding pockets in S. aureus thymidylate kinase (as set forth in Figure 2) of at most about 2.1 ~. How this calculation is obtained is described below.
Accordingly, the invention provides molecules or molecular complexes comprising an S. aureus thymidylate kinase substrate binding pocket or S aureus thyrnidylate kinase-like substrate binding pocket, as defined by the sets of structure coordinates described above.
Three-dimensional Configurations X-ray structure coordinates define a unique configuration of points in space. Those of skill in the art understand that a set of structure coordinates for protein or an protein/ligand complex, or a portion thereof, define a relative set of points that, in turn, define a configuration in three dimensions. A similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between coordinates remain essentially the same. In addition, a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.
The present invention thus includes the scalable three-dimensional configuration of points derived from the structure coordinates of at least a portion of an S. aureus thymidylate kinase molecule or molecular complex, as listed in Figure 2, as well as structurally equivalent configurations, as described below. Preferably, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of a plurality of the amino acids defining an S. aureus thymidylate kinase substrate binding pocket.
In one embodiment, the scalable three-dimensional configuration includes points derived from structure coordinates S representing the locations the backbone atoms of a plurality of amino acids defining the S. aureus thymidylate kinase TMP substrate binding pocket, preferably the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3.
Alternatively, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of the side chain and the backbone atoms (other than hydrogens) of a plurality of the amino acids defining the S. aureus thymidylate kinase TMP substrate binding pocket, preferably the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3.
In another embodiment, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations the backbone atoms of a plurality of amino acids defining the S. aureus thymidylate kinase TMP/ATP substrate binding pocket, preferably the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6. Alternatively, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of the side chain and the backbone atoms (other than hydrogens) of a plurality of the amino acids defining the S. aureus thymidylate kinase TMP/ATP substrate binding pocket, preferably the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6.
Likewise, the invention also includes the scalable three-dimensional configuration of points derived from structure coordinates of molecules or molecular complexes that are structurally homologous to S.
aureus thymidylate kinase, as well as structurally equivalent configurations.
Structurally homologous molecules or molecular complexes are defined below. Advantageously, structurally homologous molecules can be identified using the structure coordinates of S. aureus thymidylate kinase according to a method of the invention.
The configurations of points in space derived from structure coordinates according to the invention can be visualized as, for example, a holographic image, a stereodiagram, a model or a computer-displayed image, and the invention thus includes such images, diagrams or models.
Structurally Eguivalent Crystal Structures Various computational analyses can be used to determine whether a molecule or a substrate binding pocket portion thereof is "structurally equivalent," defined in terms of its three-dimensional structure, to all or part of S aureus thymidylate kinase or its substrate binding pockets.
Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, CA) version 4.1, and as described in the accompanying User's Guide.
The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. The procedure used in Molecular Similarity to compare structures is divided into four steps: (1) load the structures to be compared; (2) define the atom equivalences in these structures; (3) perform a fitting operation; and (4) analyze the results.
Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, Ca, C, and O) for all conserved residues between the two structures being compared. A
conserved residue is defined as a residue which is structurally or functionally equivalent. Only rigid fitting operations are considered.
When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by QUANTA.
For the purpose of this invention, any molecule or molecular complex or substrate binding pocket thereof, or any portion thereof, that has a root mean square deviation of conserved residue backbone atoms (N, Ca, C, O) of less than about 2.1 t~, when superimposed on the relevant backbone atoms described by the reference structure coordinates listed in Figure 2, is considered "structurally equivalent" to the reference molecule. That is to say, the crystal structures of those portions of the two molecules are substantially identical, within acceptable error. Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates listed in Figure 2 ~ a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 t~. More preferably, the root mean square deviation is less than about 1.0 ~. Another embodiment of this invention is a molecular complex defined by the structure coordinates listed in Figure 2 for those amino acids listed in Table 1, ~ a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 ~, preferably less than about 1.0 ~ . Still another embodiment of this invention is a molecular complex defined by the structure coordinates listed in Figure 2 for those amino acids listed in Table 4, t a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 ~, preferably less than about 1.0 t~.
The term "root mean square deviation" means the square root of the arithmetic mean of the squares of the deviations. It is a way to express the deviation or variation from a trend or object. For purposes of this invention, the "root mean square deviation" defines the variation in the backbone of a protein from the backbone of S. aureus thymidylate kinase or a substrate binding pocket portion thereof, as defined by the structure coordinates of S. aureus thymidylate kinase described herein.
Machine Readable Stora~ye Media Transformation of the structure coordinates for all or a portion of S. aureus thymidylate kinase or the S. aureus thymidylate kinase/ligand complex or one of its substrate binding pockets, for structurally homologous molecules as defined below, or for the structural equivalents of any of these molecules or molecular complexes as defined above, into three-dimensional graphical representations of the molecule or complex can be conveniently achieved through the use of commercially-available software.
The invention thus further provides a machine-readable storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of any of the molecule or molecular complexes of this invention that have been described above. In a preferred embodiment, the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex comprising all or any parts of an S. aureus thymidylate kinase substrate binding pocket or an S. aureus thymidylate kinase-like substrate binding pocket, as defined above. In another preferred embodiment, the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of all of the amino acids listed in Figure 2, ~ a root mean square deviation from the backbone atoms of said amino acids of not more than 2.1 ~.
In an alternative embodiment, the machine-readable data storage medium comprises a data storage material encoded with a first set of machine readable data which comprises the Fourier transform of the structure coordinates set forth in Figure 2, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data comprising the x-ray diffraction pattern of a molecule or molecular complex to determine at least a portion of the structure coordinates corresponding to the second set of machine readable data.
For example, a system for reading a data storage medium may include a computer comprising a central processing unit ("CPU"), a working memory which may be, e.g., RAM (random access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube ("CRT") displays, light emitting diode ("LED") displays, liquid crystal displays ("LCDs"), electroluminescent displays, vacuum fluorescent displays, field emission displays ("FEDs"), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, track balls, touch pads, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus. The system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the Internet) to other systems (e.g., computers, hosts, servers, etc.). The system may also include additional computer controlled devices such as consumer electronics and appliances.
Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device.
Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices. By way of example, the output hardware may include a display device for displaying a graphical representation of a binding pocket of this invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.
In operation, a CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. References to components of the hardware system are included as appropriate throughout the following description of the data storage medium.
Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof. Examples of such data storage devices include, but are not limited to, hard disk devices, CD
devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device. It should be understood that these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.
Structurally Homologous Molecules, Molecular Completes, and Crystal Structures The structure coordinates set forth in Figure 2 can be used to aid in obtaining structural information about another crystallized molecule or molecular complex. The method of the invention allows determination of at least a portion of the three-dimensional structure of molecules or molecular complexes which contain one or more structural features that are similar to structural features of S. aureus thymidylate kinase, These molecules are referred to herein as "structurally homologous" to S. aureus thymidylate kinase, Similar structural features can include, for example, regions of amino acid identity, conserved active site or binding site motifs, and similarly arranged secondary structural elements (e.g., a helices and (3 sheets). Optionally, structural homology is determined by aligning the residues of the two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize-the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. Preferably, two amino acid sequences are compared using the Blastp program, version 2Ø9, of the BLAST 2 search algorithm, as described by Tatiana et al., FEMS
Microbiol Lett 174, 247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix =
BLOSUM62; open gap penalty =11, extension gap penalty = 1, gap x dropoff = 50, expect = 10, wordsize = 3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as "identity." Preferably, a structurally homologous molecule is a protein that has an amino acid sequence sharing at least 65%
identity with a native or recombinant amino acid sequence of S. aureus thymidylate kinase (for example, SEQ m NO:1 ). More preferably, a protein that is structurally homologous to S. aureus thymidylate kinase includes at least one contiguous stretch of at least 50 amino acids that shares at least 80% amino acid sequence identity with the analogous portion of the native or recombinant S. aureus thymidylate kinase (for example, SEQ ID NO:1).
Methods for generating structural information about the structurally homologous molecule or molecular complex are well-known and include, for example, molecular replacement techniques.
Therefore, in another embodiment this invention provides a method of utilizing molecular replacement to obtain structural information about a molecule or molecular complex whose structure is unknown comprising the steps of (a) crystallizing the molecule or molecular complex of unknown structure;
(b) generating an x-ray diffraction pattern from said crystallized molecule or molecular complex; and (c) applying at least a portion of the structure coordinates set forth in Figure 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of the molecule or molecular complex whose structure is unknown.
By using molecular replacement, all or part of the structure coordinates of S. aureus thyrnidylate kinase or the S. aureus thymidylate kinase/ligand complex as provided by this invention can be used to determine the structure of a crystallized molecule or molecular complex whose structure is unknown more quickly and efficiently than attempting to determine such information ab initio.
Molecular replacement provides an accurate estimation of the phases for an unknown structure. Phases are a factor in equations used to solve crystal structures that cannot be determined directly. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time-consuming process that involves iterative cycles of approximations and refinements and greatly hinders the solution of crystal structures. However, when the crystal structure of a protein containing at least a structurally homologous portion has been solved, the phases from the known structure provide a satisfactory estimate of the phases for the unknown structure.
Thus, this method involves generating a preliminary model of a molecule or molecular complex whose structure coordinates are unknown, by orienting and positioning the relevant portion of S. aureus thymidylate kinase or the S. aureus thymidylate kinase/ligand complex according to Figure 2 within the unit cell of the crystal of the unknown molecule or molecular complex so as best to account for the observed x-ray diffraction pattern of the crystal of the molecule or molecular complex whose structure is unknown. Phases can then be calculated from this model and combined with the observed x-ray diffraction pattern amplitudes to generate an electron density map of the structure whose coordinates are unknown. This, in turn, can be subj ected to any well-known model building and structure refinement techniques to provide a final, accurate structure of the unknown crystallized molecule or molecular complex (E. Lattman, "Use of the Rotation and Translation Functions," in Meth. E, 115, pp. 55-77 (1985); M.G. Rossman, ed., "The Molecular Replacement Method," Int. Sci.
Rev. Ser., No. 13, Gordon & Breach, New York (1972)).
Structural information about a portion of any crystallized molecule or molecular complex that is sufficiently structurally homologous to a portion of S. aureus thymidylate kinase can be resolved by this method.
In addition to a molecule that shares one or more structural features with S
aureus thymidylate kinase as described above, a molecule that has similar bioactivity, such as the same catalytic activity, substrate specificity or ligand binding activity as S. aureus thymidylate kinase, may also be sufficiently structurally homologous to S. aureus thyrnidylate kinase to permit use of the structure coordinates of S aureus thyrnidylate kinase to solve its crystal structure.
In a preferred embodiment, the method of molecular replacement is utilized to obtain structural information about a molecule or molecular complex, wherein the molecule or molecular complex comprises at least one S. aureus thymidylate kinase subunit or homolog. A "subunit"
of S. aureus thymidylate kinase is an S. aureus thymidylate kinase molecule that has been truncated at the N-terminus or the C-terminus, or both. In the context of the present invention, a "homolog" of S. aureus thymidylate kinase is a protein that contains one or more amino acid substitutions, deletions, additions, or rearrangements with respect to the amino acid sequence of S. aureus thymidylate kinase (SEQ m NO:1), but that, when folded into its native conformation, exhibits or is reasonably expected to exhibit at least a portion of the tertiary (three-dimensional) structure of S
aureus thymidylate kinase, For example, structurally homologous molecules can contain deletions or additions of one or more contiguous or noncontiguous amino acids, such as a loop or a domain. Structurally homologous molecules also include "modified" S. aureus thymidylate kinase molecules that have been chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- temninal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.
A heavy atom derivative of S. aureus thymidylate kinase is also included as an S. aureus thymidylate kinase homolog. The term "heavy atom derivative" refers to derivatives of S. aureus thyrnidylate kinase produced by chemically modifying a crystal of S.,aureus thymidylate kinase, In practice, a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thiomersal or uranyl acetate, which can diffuse through the crystal and bind to the surface of the protein. The locations) of the bound heavy metal atoms) can be determined by x-ray diffraction analysis of the soaked crystal. This information, in turn, is used to generate the phase information used to construct three-dimensional structure of the protein (T.L. Blundell and N.L. Johnson, Protein Cr~rstallogrraphy, Academic Press (1976)).
Because S. aureus thymidylate kinase can crystallize in more than one crystal form, the structure coordinates of S. aureus thymidylate kinase as provided by this invention are particularly useful in solving the structure of other crystal forms of S. aureus thymidylate kinase or S. aureus thymidylate kinase complexes.
The structure coordinates of S. aureus thymidylate kinase as provided by this invention are particularly useful in solving the structure of S. aureus thymidylate kinase mutants. Mutants may be prepared, for example, by expression of S. aureus thymidylate kinase cDNA previously altered in its coding sequence by oligonucleotide-directed mutagenesis.
Mutants may also be generated by site-specific incorporation of unnatural amino acids into thymidylate kinase proteins using the general biosynthetic method of C.J. Noren et al., Science, 244:182-188 (1989). In this method, the codon encoding the amino acid of interest in wild-type S aureus thymidylate kinase is replaced by a "blank" nonsense codon, TAG, using oligonucleotide-directed mutagenesis. A suppressor tRNA directed against this codon is then chemically aminoacylated in vitro with the desired unnatural amino acid. The aminoacylated tRNA is then added to an in. vitro translation system to yield a mutant S aureus thymidylate kinase with the site-specific incorporated unnatural amino acid.
Selenocysteine or selenomethionine may be incorporated into wild-type or mutant S. aureus thymidylate kinase by expression of S. aureus thymidylate kinase-encoding cDNAs in auxotrophic E. coli strains (W.A.
Hendrickson et al., EMBO J., 9(5):1665-1672 (1990)). In this method, the wild-type or mutagenized S. aureus thymidylate kinase cDNA may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both). Alternatively, selenomethionine analogues may be prepared by down regulation methionine biosynthesis. (T.E. Benson et al., Nat. Struct. Biol., 2:644-53 (1995); G.D. Van Duyne et al., J. Mol. Biol.
229:105-24 (1993)).
The structure coordinates of S. aureus thymidylate kinase listed in Figure 2 are also particularly useful to solve the structure of crystals of S. aureus thymidylate kinase, S. aureus thymidylate kinase mutants or S.
aureus thymidylate kinase homologs co-complexed with a variety of chemical entities. This approach enables the determination of the optimal sites for interaction between chemical entities, including candidate S. aureus thymidylate kinase inhibitors and S. aureus thymidylate kinase. Potential sites for modification within the various binding site of the molecule can also be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between S. aureus thymidylate kinase and a chemical entity. For example, high resolution x-ray diffraction data collected from crystals exposed to different types of solvent allows the determination of where each type of solvent molecule resides. Small molecules that bind tightly to those sites can then be designed and synthesized and tested for their S. aureus thymidylate kinase inhibition activity.
All of the complexes referred to above may be studied using well-known x-ray diffraction techniques and may be refined versus 1.5-3 ~
resolution x-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, 81992, distributed by Molecular Simulations, Inc.; see, e.g., Blundell & Johnson, supra; Meth.
Enz~ol., Vol. 114 & 115, H.W. Wyckoff et al., eds., Academic Press (1985)). This information may thus be used to optimize known S. aureus thymidylate kinase inhibitors, and more importantly, to design new S.
aureus thymidylate kinase inhibitors.
The invention also includes the unique three-dimensional configuration defined by a set of points defined by the structure coordinates for a molecule or molecular complex structurally homologous to S. aureus thymidylate kinase as determined using the method of the present invention, structurally equivalent configurations, and magnetic storage media comprising such set of structure coordinates.
Further, the invention includes structurally homologous molecules as identified using the method of the invention.
Homolo~w Modeling Using homology modeling, a computer model of an S aureus thymidylate kinase homolog can be built or refined without crystallizing the homolog. First, a preliminary model of the S. aureus thymidylate kinase homolog is created by sequence alignment with S aureus thymidylate kinase, secondary structure prediction, the screening of structural libraries, or any combination of those techniques. Computational software may be used to carry out the sequence alignments and the secondary structure predictions. Structural incoherences, e.g., structural fragments around insertions and deletions, can be modeled by screening a structural library for peptides of the desired length and with a suitable conformation. For prediction of the side chain conformation, a side chain rotamer library may be employed. If the S. aureus thymidylate kinase homolog has been crystallized, the final homology model can be used to solve the crystal structure of the homolog by molecular replacement, as described above.
Next, the preliminary model is subjected to energy minimization to yield an energy minimized model. The energy minimized model may contain regions where stereochemistry restraints are violated, in which case such regions are remodeled to obtain a final homology model. The homology model is positioned according to the results of molecular replacement, and subjected to further refinement comprising molecular dynamics calculations.
Rational Drug DesiEn Computational techniques can be used to screen, identify, select and/or design chemical entities capable of associating with S aureus thymidylate kinase or structurally homologous molecules. Knowledge of the structure coordinates for S. aureus thymidylate kinase permits the design and/or identification of synthetic compounds and/or other molecules which have a shape complementary to the conformation of the S. aureus thymidylate kinase binding site. In particular, computational techniques can be used to identify or design chemical entities, such as inhibitors, agonists and antagonists, that associate with an S aureus thymidylate kinase substrate binding pocket or an S. aureus thymidylate kinase-like substrate binding pocket. Inhibitors may bind to or interfere with all or a portion of an active site of S. aureus thymidylate kinase, and can be competitive, non-competitive, or uncompetitive inhibitors; or interfere with dimerization by binding at the interface between the two monomers. Once identified and screened for biological activity, these inhibitors/agonists/antagonists may be used therapeutically or prophylactically to block S. aureus thymidylate kinase activity and, thus, inhibit the growth of the bacteria or cause its death.
Structure-activity data for analogues of ligands that bind to or interfere with S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pockets can also be obtained computationally.
The term "chemical entity," as used herein, refers to chemical compounds, complexes of two or more chemical compounds, and fragments of such compounds or complexes. Chemical entities that are determined to associate with S. aureus thyrnidylate kinase are potential drug candidates.
Data stored in a machine-readable storage medium that is capable of displaying a graphical three-dimensional representation of the structure of S aureus thymidylate kinase or a structurally homologous molecule, as identified herein, or portions thereof may thus be advantageously used for drug discovery. The structure coordinates of the chemical entity are used to generate a three-dimensional image that. can be computationally fit to the three-dimensional image of S. aureus thymidylate kinase or a structurally homologous molecule. The three-dimensional molecular structure encoded by the data in the data storage medium can then be computationally evaluated for its ability to associate with chemical entities. When the molecular structures encoded by the data is displayed in a graphical three-dimensional representation on a computer screen, the protein structure can also be visually inspected for potential association with chemical entities.
One embodiment of the method of drug design involves evaluating the potential association of a known chemical entity with S
aureus thymidylate kinase or a structurally homologous molecule, particularly with an S. aureus thyrnidylate kinase substrate binding pocket or S. aureus thyrnidylate kinase-like substrate binding pocket. The method of drug design thus includes computationally evaluating the potential of a selected chemical entity to associate with any of the molecules or molecular complexes set forth above. 'This method comprises the steps of (a) employing computational means to perform a fitting operation between the selected chemical entity and a substrate binding pocket or a pocket nearby the substrate binding pocket of the molecule or molecular complex;
and (b) analyzing the results of said fitting operation to quantify the association between the chemical entity and the substrate binding pocket.
In another embodiment, the method of drug design involves computer-assisted design of chemical entities that associate with S. aureus thymidylate kinase, its homologs, or portions thereof. Chemical entities can be designed in a step-wise fashion, one fragment at a time, or may be designed as a whole or "de novo."
To be a viable drug candidate, the chemical entity identified or designed according to the method must be capable of structurally associating with at least part of an S. aureus thymidylate kinase or S aureus thymidylate kinase-like substrate binding pockets, and must be able, sterically and energetically, to assume a conformation that allows it to associate with the S. aureus thymidylate kinase or S. aureus thyrnidylate kinase-like substrate binding pocket. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions.
Conformational considerations include the overall three-dimensional structure and orientation of the chemical entity in relation to the substrate binding pocket, and the spacing between various functional groups of an entity that directly interact with the S. aureus thymidylate kinase-like substrate binding pocket or homologs thereof.
Optionally, the potential binding of a chemical entity to an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket is analyzed using computer modeling techniques prior to the actual synthesis and testing of the chemical entity. If these computational experiments suggest insufficient interaction and association between it and the S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket, testing of the entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to or interfere with an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. Binding assays to determine if a compound actually interferes with S. aureus thymidylate kinase can also be performed and are well known in the art. Binding assays may employ kinetic or thermodynamic methodology using a wide variety of techniques including, but not limited to, microcalorimetry, circular dichroism, capillary zone electrophoresis, nuclear magnetic resonance spectroscopy, fluorescence spectroscopy, and combinations thereof.
One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. This process may begin by visual inspection of, for example, an S aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket on the computer screen based on the S. aureus thymidylate kinase structure coordinates listed in Figure 2 or other coordinates which define a similar shape generated from the machine-readable storage medium. Selected fragments or chemical entities may then be positioned in a variety of orientations, or docked, within the substrate binding pocket. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.
Specialized computer programs may also assist in the process of selecting fragments or chemical entities. Examples include GRID (P.J.
Goodford, J. Med. Chem. 28:849-857 (1985); available from Oxford University, Oxford, UK); MCSS (A. Miranker et al., Proteins: Struct. Funct.
Gen.,11:29-34 (1991); available from Molecular Simulations, San Diego, CA); AUTODOCK (D.S. Goodsell et al., Proteins: Struct. Funct. Genet.
8:195-202 (1990); available from Scripps Research Institute, La Jolla, CA);
and DOCK (LD. Kuntz et al., J. Mol. Biol. 161:269-288 (1982); available from University of California, San Francisco, CA).
Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or complex.
Assembly may be preceded by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure coordinates of S. aureus thymidylate kinase. This would be followed by manual model building using software such as QUANTA or SYBYL (Tripos Associates, St. Louis, MO).
Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include, without limitation, CAVEAT (P.A. Bartlett et al., in Molecular Recognition in Chemical and Biological Problems," Special Publ., Royal Chem. Soc., 78:182-196 (1989);
G. Lauri et al., J. Comput. Aided Mol. Des. 8:51-66 (1994); available from the University of California, Berkeley, CA); 3D database systems such as ISIS (available from MDL Information Systems, San Leandro, CA;
reviewed in Y.C. Martin, J. Med. Chem. 35:2145-2154 (1992)); and HOOK
(M.B. Eisen et al., Proteins: Struc., Funct., Genet. 19:199-221 (1994);
available from Molecular Simulations, San Diego, CA).
S. aureus thymidylate kinase binding compounds may be designed "de novo" using either an empty binding site or optionally including some portions) of a known inhibitor(s). There are many de novo ligand design methods including, without limitation, LUDI (H.-J. Bohm, J.
Comp. Aid. Molec. Design. 6:61-78 (1992); available from Molecular Simulations Inc., San Diego, CA); LEGEND (Y. Nishibata et al., Tetrahedron, 47:8985 (1991); available from Molecular Simulations Inc., San Diego, CA); LeapFrog (available from Tripos Associates, St. Louis, MO); and SPROUT (V. Gillet et al., J. Comput. Aided Mol. Design 7:127-153 (1993); available from the University of Leeds, UK).
Once a compound has been designed or selected by the above methods, the efficiency with which that entity may bind to or interfere with an S aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket may be tested and optimized by computational evaluation. For example, an effective S. aureus thymidylate kinase or S.
aureus thymidylate kinase-like substrate binding pocket inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding). Thus, the most efficient S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole;
more preferably, not greater than 7 kcal/mole. S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket inhibitors may interact with the substrate binding pocket in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free entity and the average energy of the conformations observed when the inhibitor binds to the protein.
An entity designed or selected as binding to or interfering with an S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme and with the surrounding water molecules. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole, and charge-dipole interactions.
Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interactions. Examples of programs designed for such uses include: Gaussian 94, revision C (M.J.
Frisch, Gaussian, Inc., Pittsburgh, PA 81995); AMBER, version 4.1 (P.A.
Kollman, University of California at San Francisco, 81995);
QUANTA/CHARMM (Molecular Simulations, Inc., San Diego, CA 81995);
Insight II/Discover (Molecular Simulations, Inc., San Diego, CA 81995);
Delphi (Molecular Simulations, Inc., San Diego, CA 81995); and AMSOL
(Quantum Chemistry Program Exchange, Indiana University). These programs may be implemented, for instance, using a Silicon Graphics workstation such as an Indigo2 with "IIVVIPACT" graphics. Other hardware systems and software packages will be known to those skilled in the art.
Another approach encompassed by this invention is the computational screening of small molecule databases for chemical entities or compounds that can bind in whole, or in part, to a S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. In this screening, the quality of fit of such entities to the binding site may be judged either by shape complementarity or by estimated interaction energy (E.C.
Meng et al., J. Comp. Chem., 13, pp. 505-524 (1992)).
This invention also enables the development of chemical entities that can isomerize to short-lived reaction intermediates in the chemical reaction of a substrate or other compound that interferes with or with S. aureus thymidylate kinase. Time-dependent analysis of structural changes in S. aureus thymidylate kinase during its interaction with other molecules is carned out. The reaction intermediates of S. aureus thymidylate kinase can also be deduced from the reaction product in co-complex with S. aureus thymidylate kinase. Such information is useful to design improved analogues of known S. aureus thymidylate kinase inhibitors or to design novel classes of inhibitors based on the reaction intermediates of the S. aureus thymidylate kinase and inhibitor co-complex.
This provides a novel route for designing S. aureus thymidylate kinase inhibitors with both high specificity and stability.
Yet another approach to rational drug design involves probing the S aureus thymidylate kinase crystal of the invention with molecules comprising a variety of different functional groups to determine optimal sites for interaction between candidate S. aureus thymidylate kinase inhibitors and the protein. For example, high resolution x-ray diffraction data collected from crystals soaked in or co-crystallized with other molecules allows the determination of where each type of solvent molecule sticks. Molecules that bind tightly to those sites can then be further modified and synthesized and tested for their thymidylate kinase inhibitor activity (J. Travis, Science, 262:1374 (1993)).
1n a related approach, iterative drug design is used to identify inhibitors of S aureus thymidylate kinase. Iterative drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional structures of successive sets of protein/compound complexes. In iterative drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional structures of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex. This is accomplished by selecting compounds with inhibitory activity, obtaining crystals of this new protein/compound complex, solving the three dimensional structure of the complex, and comparing the associations between the new protein/compound complex and previously solved protein/compound complexes. By observing how changes in the compound affected the protein/compound associations, these associations may be optimized.
A compound that is identified or designed as a result of any of these methods can be obtained (or synthesized) and tested for its .
biological activity, e.g., inhibition of thymidylate kinase activity.
Pharmaceutical Compositions Inhibitors) Pharmaceutical compositions of this invention comprise an inhibitor of S. aureus TMK activity identified according to the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable Garner, adjuvant, or vehicle. The term "pharmaceutically acceptable carrier" refers to a carriers) that is "acceptable" in the sense of being compatible with the other ingredients of a.composition and not deleterious to the recipient thereof. Optionally, the pH of the formulation is adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability of the formulated compound or its delivery form.
Methods of making and using such pharmaceutical compositions are also included in the invention. The pharmaceutical compositions of the invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration or administration by injection is preferred. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, infra-articular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.
Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the S. aureus TMK inhibitory compounds described herein are useful for the prevention and treatment of S. aureus TMK mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the Garner materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80%
active compound.
In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1: Analysis of the Structure of S. aureus Th~ylate Kinase A. Expression, Purification and Crystallization The M15-1C Escherichia coli construct expressing S. aureus thymidylate kinase was obtained as a strain in which the Qiagen pREP4 vector was replaced with pREP4UX. Genes and polypeptides derived from S aureus, including S. aureus and thymidylate kinase, are published in EP
786519 A2 and WO 0012678, both assigned to Human Genome Sciences.
This plasmid contains the argU gene which codes for the AGA tRNA and prevents the lysine for arginine substitution which occurred in the original construct from Human Genome Sciences. For preparation of the selenomethionine analogue of thymidylate kinase, the construct was grown in a minimal salts medium, M9, which contained glucose and NH4C1 as the sources of carbon and nitrogen. Endogenous methionine biosynthesis was then inhibited while adding an excess of selenomethionine to the growth medium just prior to IPTG induction of thymidylate kinase synthesis (T.E.
Benson et al., Nat. Struct. Biol., 2:644-53 (1995); G.D. Van Duyne et al., J.
Mol. Biol. 229:105-24 (1993)). The formulation of basal M9 was Na2HP04, 6 g; KH2PO4, 3 g; NH4Cl, 1.0 g; and NaCI, 0.5 g per L of deionized water.
T'he pH was adjusted to 7.4 with concentrated KOH and the medium was sterilized by autoclaving. Prior to inoculation, the following filter sterilized solutions were added per L of basal medium: 1M MgS04, 1.0 mL; 1M
CaCl2, 0.1 mL; trace metal salts solution, 0.1 mL, 10 mM thiamin, 1.0 mL;
and 20% glucose, 20 mL. The trace metal salts solution contained per L of deionized water: MgC12~6H20, 39.44 g; MnS04~H20, 5.58 g; FeS04~7H20, 1.11 g; NaZMo04~2H20, 0.48 g; CaCl2, 0.33 g; NaCI, 0.12 g; and ascorbic acid, 1.0 g. Filter sterilized ampicillin and kanamycin were added to the medium at final concentrations of 100 mg/mL and 30mg/mL, respectively.
Fermentations were prepared in 100 mL volumes of M9 medium contained in 500 mL wide mouth flasks. A 0.1 mL aliquot of the stock culture was inoculated into the medium and allowed to grow at 30°C
for 18 - 20 hours with a shaking rate of 200 rpm. The seed culture was harvested by centrifugation and then resuspended in an equal volume of M9 medium. The resuspended seed was used to inoculate expression fermentations at a rate of 3%. For expression, the culture was grown under the same conditions to an A600 of ~0.6. At this point, methionine biosynthesis was down regulated by the addition of L-lysine, L-threonine, and L-phenylalanine at a final concentration for each of 100 mg/mL and L-leucine, L-isoleucine, and L-valine at 50 mg/mL each.
D,L-selenomethionine was added simultaneously to a final concentration of 100 mg/mL. After 15 - 20 minutes, expression of thyrnidylate kinase was induced by addition of IPTG (isopropyl thio-(3-D-galactosidase, Gibco BRL) to 1 mM. Growth of the culture was continued for an additional 3.5 hours until an A600 of 1.5 - 1.6. Cells were then harvested by centrifugation and frozen at -80°C. Under these conditions, the average yield of cell paste was 3.0 to 3.5 g/L.
For protein purification, all buffers were chilled to 4°C prior to use and all procedures were performed at 4°C. Cells (24.8 g wet weight) were resuspended in 125 mL of lysis buffer (25 mM Tris (pH 7.8), 500 mM
NaCI, 10% glycerol, 25 mM imidazole, 5 mM 2-mercaptoethanol, 0.2 mg/mL DNAse I) and ruptured by using an American Instrument French Press at 16,000 PSI. The lysate was clarified by centrifugation at 39,200 X g for 60 minutes in a JA20 rotor. The supernatant was filtered by using a Nalgene 0.2 ~m filter unit. The filtered supernatant was applied at 74 cm/hr to a Qiagen NTA Superflow column (1.6 cm i.d. X 11 cm (CV = 22 mL)) charged with nickel that was pre-equilibrated with EQ buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10% glycerol, 25 mM imidazole, 5 mM
2-mercaptoethanol). The column was washed with 7.7 CV of EQ buffer, 12.5 CV of wash buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10%
glycerol, 50 mM imidazole, 5 mM 2-mercaptoethanol) and eluted with 1.4 CV of elution buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10% glycerol, 300 mM imidazole, 5 mM 2-mercaptoethanol). During the elution the linear velocity was decreased to 42 cm/hr. The eluted fraction was treated with DTT to achieve a final concentration of 10 mM and dialyzed extensively against nitrogen sparged dialysis buffer (25 mM Tris (pH 7.8), 500 mM
NaCI, 10% glycerol, 10 mM DTT, pH 7.8).
The Mono Q analytical run was performed using 50 mL
native TMK (14 mg/mL) diluted to 200 mL with 20 mM Tris (pH 8.0). The sample was loaded onto a Mono Q (Amersham Pharmacia Biotech) column equilibrated with 20 mM Tris (pH 8.0) and run through a 20-40% (20 mM
Tris (pH 8.0) + 1.0M NaCI) gradient in 40 mL with a flow rate of 1.0 mL/min. The Mono P column run was performed using 50 mL TMK
(l4mg/mL) diluted to 200 mL with 25 mM bis-Tris (pH 6.71). The sample was injected onto a Mono P column (Amersham Pharmacia Biotech) equilibrated with 25 mM bis-Tris (pH 6.71 ) and run through a step gradient of 0-100-0 % Polybuffer Mix 96/74 (20:1), pH 5.80. Gel filtration studies were carried out on a Superose 200 column with a 500 mL sample of thymidylate kinase at a concentration of 4.2 mg/mL using 50 mM Tris (pH
8.5), 500 mM NaCI, 5 mM 2-mercaptoethanol, and 0.5% glycerol at a flow rate of 1 mL/min. For dynamic light scattering experiments, samples were mixed in 1.5m1 eppendorf tubes, then sterile filtered through a 0.22 mm ceramic membrane (Whatman). 20 mL of solution is read in a quartz cuvette in a Dyna Pro Molecular Sizing Instrument (Protein Solutions, Inc., Charlottesville, VA).
The native protein was exchanged into 50 mM Tris (pH 7.8), 5 mM 2-mercaptoethanol to a concentration of 15 mg/mL and screened for crystallization conditions using Crystal Screen I, Crystal Screen II, and MembFac Screen (Hampton Research, Laguna Niguel, CA). The most encouraging lead was from Hampton Crystal Screen I condition 23: 30%
PEG 400, O.1M Na HEPES pH 7.5, 0.2M MgCl2. Follow up screens indicated that PIPES buffer was most conducive to crystal formation.
The initial crystals of the thymidylate kinase were stacks of small plates that were inseparable and unusable for diffraction studies.
Biochemical analysis of the protein revealed that the sample was substantially pure by sodium dodecylsulfate polyacrylamide-gel electrophoresis (SDS-PAGE) analysis, but isoelectric focusing (IEF) gels revealed at least two distinct isoelectric species. It is likely, although yet unproven, that these isoelectric species were the cause of the morphology of the thymidylate kinase crystals. Further efforts at purification with a Mono Q column indicated that separation of these species would be difficult and it was not clear that large scale isoelectrofocusing using a Mono P column or preparative isoelectric focusing would improve the separation because of the small differences in pI. A series experiments exploring the feasibility of preparative isoelectric focusing experiments using PrIME (preparative isoelectric membrane electrophoresis) was hampered due to precipitation of the protein near its pI. Gel filtration did reveal that thymidylate kinase behaves as a dimer in solution, confirming earlier literature reports for the related E coli and yeast TMK. The initial crystallization conditions S contained 200 mM MgCl2 and later experiments showed that at least 150 mM MgCl2 was required for crystal formation. Dynamic light scattering experiments in the presence of MgCl2 revealed an interesting phenomenon where protein aggregation was reduced in the presence of MgCl2 over a number of hours leading to a monodisperse, dimeric sample suitable for crystallization.
The stacked plates were eventually transformed into single crystals through iterative streak seeding and crystallization on hanging or sitting drops with thymidylate kinase in 0.1 M PIPES (pH 6.6), 14-19% PEG
400, 0.2 M MgCl2. This technique involved taking the multinucleated crystals, crushing them into microcrystals, and using a dilution series of this suspension of microcrystals for seeding. It was observed that this second round of crystals were usually less multinucleated than when crystal formation was allowed to proceed via spontaneous nucleation. A second round of streak seeding was usually necessary in order to obtain multiple single crystals. Refinement of the streak seeding technique resulted in native and selenomethionine TMK crystals on the order of about 100 ~m x about 100 ~m x about 20 Vim.
Subsequent crystallization experiments also indicated that a protein concentration of 7 mg/mL was able to yield suitable crystals. The crystallization solution was a cryoprotective agent making it straightforward to freeze the crystals in liquid nitrogen for data collection.
Selenomethionine thymidylate kinase was exchanged into 10 mM Tris (pH
7.8), 10 mM DTT and concentrated to 7 or 14 mg/mL for crystallization experiments.
B. X-ray Diffraction Characterization Thymidylate kinase crystals were generally too small for useful data collection using standard x-ray diffraction equipment.
Therefore, all data collection was carried out at the Advanced Photon Source (Argonne, IL). The structure of S aureus thymidylate kinase was determined by multiple anomalous dispersion (MAD) using synchrotron radiation. Crystals were of the space group P21 with cell constants a = 49.8 A, b = 90.1 ~, c= 46.5 ~, a~y=90° and ~3 = 101.8°. The Matthews coefficient for these crystals assuming that there are two molecules in the asymmetric unit is 2.1 ~/Da with 40% solvent. Two MAD data sets were collected B one at 2.7 ~ and one at 2.3 ~.
Two selenomethionine multiple anomalous dispersion (MAD) experiments were performed (2.7~ resolution and 2.3 ~ resolution) using three different wavelengths (remote wavelength 1.0332 ~, 12000 eV, inflection point wavelength 0.979746 ~, 12654.8 eV, and the peak wavelength 0.979617 ~, 12656.5 eV).
C. Heavy Atom Derivative Selenomethionine thymidylate kinase was expressed using downregulation of methionine biosynthesis (T.E. Benson et al., Nat. Struct.
Biol., 2:644-53 (1995); G.D. Van Duyne et al., J. Mol. Biol. 229:105-24 (1993)) and purified in order to obtain de novo phases by multiple anomalous dispersion (W.A. Hendrickson, Science 254:51-8 (1991)).
Anomalous difference Patterson maps revealed six selenium sites (three for each of the two monomers in the asymmetric unit) (Figure 9). Patterson maps at 2.7 ~ showed that the atomic positions for the seleniums were not well resolved, but maps at 2.31 clearly defined the atomic positions of the heavy atoms. Unfortunately, the MAD phases for data collected at 2.3 ~
were of lower quality than the phases at 2.7 A, so initial model building was performed using the MAD phased map to 2.7 ~ (Figure 10). Subsequent refinement was conducted against the 2.3 ~ data, and this higher resolution structure is the one reported here.
D. Phase Combination Each of these individual data sets was indexed and integrated separately (see Tables 7 and 8 for integration statistics). The data sets were scaled to each other using the program SCALEIT in the CCP4 Program Suite (Collaborative Computational Project N4, Acta Cr ~~st. D50:760-3 (1994)). Patterson maps revealed six selenium sites (three for each monomer in the asymmetric unit) whose locations were determined by direct methods using SHELX (G.M. Sheldrick & R.O. Gould, Acta Cr ~~st.
B51:423-31 (1995)). Heavy atom refinement and phase calculations were conducted using SHARP (E. La Fortelle et al., A Maximum-Likelihood Heavy-Atom Parameter Refinement and Phasing Program for the M1R and MAD Methods, P. Bourne & K. Watenpaugh, eds., C .r~tallog_raphic Computing 7 (1997)). Phases calculated in SHARP were solvent flattened using the program SOLOMON (Collaborative Computational Project N4, Acta Cryst. D50:760-3 (1994)) and gave a significantly improved electron density map.
Table 7. Data collection and phasing statistics for structure of S. aureus TMK
~, 1.0332 ~ ~, 0.9797461 ~, 0.979617 ~
(12000 eV) (12654.8 eV) (12656.5 eV) Resolution 2.7 ~ 2.7 ~ 2.7 ~
No. observations76,132 62,273 76,145 No. unique 10,901 10,941 10,928 refl.
completeness 100% 100% 100%
RS~,I" 0.085 0.103 0.106 R~"u;s acentrics -- 0.61 0.67 R.~"u;~ anomalous 0.98 0.78 0.69 Phasing power centrics -- 1.28 1.21 acentrics -- 2.30 1.83 Mean figure of merit (to 2.7 ~ resolution) before solvent flattening 0.51 after solvent flattening 0.94 Table 8. Data collection and phasing statistics for structure of S. aureus TMK
~, 1.0332 t~ ~, 0.979746 ~ ~, 0.979617 A
(12000 eV) (12654.8 eV) (12656.5 eV) Resolution 2.3 ~ 2.3 ~ 2.3 ~
No. Observations76,712 123,553 123,372 No. unique 17,661 17,887 17,991 refl.
completeness 98.2% 99.4% 99.3%
Rsyr, 0.083 0.107 0.099 R~"u;~ acentrics -- 0.56 0.61 R~"";S anomalous 0.99 0.69 0.70 Phasing power centrics -- 1.34 1.38 acentrics -- 2.22 2.04 Mean figure of merit (to 2.3 ~ resolution) before solvent flattening 0.57 after solvent flattening 0.87 E. Model Building and Refinement At this stage in the structure solution, the coordinates for E.
coli thymidylate kinase greatly aided the process of model building for placement of the main chain backbone. Model building was done using the program CHAIN (J.S. Sack, Journal of Molecular Graphics 6:224-5 (1988)) and LORE (B.C. Finzel, Meth. Enz~. 277:230-42 (1997)). Refinement was carried out with XPLOR98 (A.T. Brunger, X-PLOR version 3.1: A
system for X-ray Crystallography and NMR, New Haven: Yale Univ. Press, (1992)) incorporating bulk solvent correction during the refinement (J.S.
Jiang & A.T. Brunger, J. Mol. Biol. 243:100-15 (1994)). Progress of the refinement was monitored by a decrease in both the R-factor and Free R-factor.
Table 9. Refinement Statistics for structure of S. aureus TMK
R-factor Free R-factor No. of reflections 20-2.3 ~ F> 2a 0.2366 0.3084 15,908 Bonds (t~) Angles(°) r.m.s deviation from ideal geometry 0.008 1.32 Number of atoms Average B-factor Protein 2978 27.2 Waters 174 3 8.9 Total 3152 27.81 Stereochemistry of the model was checked using PROCHECK (R.A. Laskowski et al., J. Appl. Cryst. 26:283-91 (1993)) revealing no residues in disallowed regions of the Ramachandran plot.
Figure 9 was made using SETOR (S.V. Evans, J. Mol. Graphics 11:134-8 (1993)) and Figures 3a, 4 were produced in MOLSCRIPT (P. Kraulis, J.
Appl. Cr ~~st. 24:946-50 (1991)) and Raster 3D (E.A. Merritt & M.E.P.
Murphy, Acta Cr~rst. D50:869-73 (1994)) while Figures Sa and 6a were produced in MOLSCRIPT (P. Kraulis, J. Ap~l. Cr ~~st. 24:946-50 (1991)) alone.
F. Assays.
Binding assays to determine if a compound actually interferes with S. aureus thymidylate kinase can also be performed. For example, thymidylate kinase activity can be measured by coupling the formation of ADP and TDP to the reactions catalyzed by PD, LDH, and NDP-Kinase, as shown below. Oxidation of NADH is accompanied by a decrease in absorbance at 340 nm, which is measured spectrophotometrically.
1 ) ATP + TMP T~'S'""d~~e K'"ase ~ ADp + TDP
2) ATP + TDP ~P~K"'~e , ADP + TTP
3) 2 ADP + 2 PEP PK 2 ATP + 2 PYRUVATE
4) 2 PYRUVATE + 2 NADH LDH 2 LACTATE +
2 NAD+
The standard reaction conditions employed during the kinetic characterization of the enzyme were: 50 mM HEPES, pH 8.0, 50 mM KCI, 2 mM MgClz, 4 U/ml PK, 5 U/ml LDH, 2 mM PEP, 1.5 mM ATP, 5 U/ml NDP-Kinase, 1.0 mM TMP, 0.22 mM NADH, and 0.8 ~g/ml T. kinase. All of the reagents except the T. Kinase were added to a cuvette and mixed, and the mixture was incubated at 24.5°C for 2 minutes. To start the reaction, the T. Kinase was added, the contents of the cuvette were mixed, and the decrease in absorbance at 340 nm was monitored for 4-5 minutes.
SEQUENCE LISTING FREE TEXT
SEQ ID NO:1 recombinant S. aureus thymidylate kinase (with polyhistidine [His6] sequence tag) SEQ ID N0:2 E coli thymidylate kinase SEQ ID N0:3 S. cerevisiae thymidylate kinase SEQUENCE LISTING
<110> Pharmacia & Upjohn <120> Crystallization and Structure Determination of Staphylococcus Aureus Thymidylate Kinase <130> 6245.PCP
<140> Unassigned <141> 2000-08-04 <150> 60/147,117 <151> 1999-08-04 <160> 3 <170> PatentIn Ver. 2.1 <210> 1 <211> 214 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Recombinant Staphylococcus aureus thymidylate kinase with 6-His tag <400> 1 Met Gly Ser Ala Phe Ile Thr Phe Glu Gly Pro Glu Gly Ser Gly Lys Thr Thr Val Ile Asn Glu Val Tyr His Arg Leu Val Lys Asp Tyr Asp Val Ile Met Thr Arg Glu Pro Gly Gly Val Pro Thr Gly Glu Glu Ile Arg Lys Ile Val Leu Glu Gly Asn Asp Met Asp Ile Arg Thr Glu Ala Met Leu Phe Ala Ala Ser Arg Arg Glu His Leu Val Leu Lys Val Ile Pro Ala Leu Lys Glu Gly Lys Val Val Leu Cys Asp Arg Tyr 11e Asp SUBSTITUTE SHEET (RULE 26) Ser Ser Leu Ala Tyr Gln Gly Tyr Ala Arg Gly Ile Gly Val Glu Glu Val Arg Ala Leu Asn Glu Phe Ala Ile Asn Gly Leu Tyr Pro Asp Leu Thr Ile Tyr Leu Asn Val Ser Ala Glu Val Gly Arg Glu Arg Ile Ile Lys Asn Ser Arg Asp Gln Asn Arg Leu Asp Gln Glu Asp Leu Lys Phe His Glu Lys Val Ile Glu Gly Tyr Gln Glu Ile Ile~His Asn Glu Ser Gln Arg Phe Lys Ser Val Asn Ala Asp Gln Pro Leu Glu Asn Val Val Glu Asp Thr Tyr Gln Thr Ile Ile Lys Tyr Leu Glu Lys Ile Arg Ser His His His His His His <210> 2 <211> 213 <212> PRT
<213> Escherichia coli <400> 2 Met Arg Ser Lys Tyr Ile Val Ile Glu Gly Leu Glu Gly Ala Gly Lys Thr Thr Ala Arg Asn Val Val Val Glu Thr Leu Glu Gln Leu Gly Ile Arg Asp Met Val Phe Thr Arg Glu Pro Gly Gly Thr Gln Leu Ala Glu Lys Leu Arg Ser Leu Val Leu Asp Ile Lys Ser Val Gly Asp Glu Val Ile Thr Asp Lys Ala Glu Val Leu Met Phe Tyr Ala Ala Arg Val Gln Leu Val Glu Thr Val Ile Lys Pro Ala Leu Ala Asn Gly Thr Trp Val SUBSTITUTE SHEET (RULE 26) Ile Gly Asp Arg His Asp Leu Ser Thr Gln Ala Tyr Gln Gly Gly Gly Arg Gly Ile Asp Gln His Met Leu Ala Thr Leu Arg Asp Ala Val Leu Gly Asp Phe Arg Pro Asp Leu Thr Leu Tyr Leu Asp Val Thr Pro Glu Val Gly Leu Lys Arg Ala Arg Ala Arg Gly Glu Leu Asp Arg Ile Glu 145 150 . 155 160 Gln Glu Ser Phe Asp Phe Phe Asn Arg Thr Arg Ala Arg Tyr Leu Glu Leu Ala Ala Gln Asp Lys Ser Ile His.Thr Ile Asp Ala Thr Gln Pro Leu Glu Ala Val Met Asp Ala Ile Arg Thr Thr Val Thr His Trp Val Lys Glu Leu Asp Ala <210> 3 <211> 216 <212> PRT
<213> Saccharomyces cerevisiae <400> 3 Met Met Gly Arg Gly Lys Leu Ile Leu Ile Glu Gly Leu Asp Arg Thr Gly Lys Thr Thr Gln Cys Asn Ile Leu Tyr Lys Lys Leu Gln Pro Asn Cys Lys Leu Leu Lys Phe Pro Glu Arg Ser Thr Arg Ile Gly Gly Leu Ile Asn Glu Tyr Leu Thr Asp Asp Ser Phe Gln Leu Ser Asp Gln Ala Ile His Leu Leu Phe Ser Ala Asn Arg Trp Glu Ile Val Asp Lys Ile Lys Lys Asp Leu Leu Glu Gly Lys Asn Ile Val Met Asp Arg Tyr Val SUBSTITUTE SHEET (RULE 26) Tyr Ser Gly Val Ala Tyr Ser Ala Ala Lys Gly Thr Asn Gly Met Asp Leu Asp Trp Cys Leu Gln Pro Asp Val Gly Leu Leu Lys Pro Asp Leu Thr Leu Phe Leu Ser Thr Gln Asp Val Asp Asn Asn Ala Glu Lys Ser Gly Phe Gly Asp Glu Arg Tyr Glu Thr Val Lys Phe Gln Glu Lys Val 145 150 155 ' 160 Lys Gln Thr Phe Met Lys Leu Leu Asp Lys Glu Ile Arg Lys Gly Asp Glu Ser Ile Thr Ile Val Asp Val Thr~Asn Lys Gly Ile Gln Glu Val Glu Ala Leu Ile Trp Gln Ile Val Glu Pro Val Leu Ser Thr His Ile Asp His Asp Lys Phe Ser Phe Phe SUBSTITUTE SHEET (RULE 26)
"Occ" is an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of "1" indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.
"B" is a thermal factor that measures movement of the atom around its atomic center.
Figure 3 depicts S aureus thymidylate kinase using (a) a ribbon diagram showing the backbone structure of the enzyme and (b) a schematic diagram showing the secondary structure for a TMK monomer Disordered loops are indicated by arrows.
Figure 4 depicts a structural comparison of E. coli TMK +
APST and S. aureus TMK. The overall fold of the two proteins is well-conserved, but note that the lid in the E. coli TMK is not present in the S.
aureus TMK due to the absence of a ligand.
Figure 5 depicts (a) a stereo view of a superposition of S.
aureus thymidylate kinase and E. coli thymidylate kinase and (b) the amino acid sequence alignment of S. aureus thymidylate kinase (SEQ ID NO:1) (capital letters, upper sequence) and E. coli thymidylate kinase (SEQ ID
N0:2) (lower sequence). Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicated by ~ and similar residues are indicated by . and : symbols.
Figure 6 depicts (a) a stereo view of a superposition of S.
aureus thymidylate kinase and S. cerevisiae thymidylate kinase and (b) the sequence alignment of S. aureus thyrnidylate kinase (SEQ ID NO:1 ) (capital letters, upper sequence) and S cerevisiae thymidylate kinase (SEQ ID
N0:3) (lower sequence). Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicated by ~ and similar residues are indicated by . and : symbols.
Figure 7 depicts a) a substrate-based inhibitor (APST) for thymidylate kinase with a Kd of 20 nM for E. coli TMK (A. Lavie et al., Biochemistry 37:3677-86 (1998); A. Lavie et al., Proc. Natl. Acad. Sci.
USA, 95:14045-50 (1998)). b) protein ligand interactions for E. coli TMK
(shaded boxes, from A. Lavie et al., Proc. Natl. Acad. Sci. USA, 95:14045-50 (1998)) with the corresponding residues from S. aureus TMK underlined (conservative mutations are marked with an asterisk). Active site residues from the S. cerevisiae are boxed (where no corresponding residue from E.
coli TMK is present, an arrow indicates the point of contact with the substrate).
Figure 8 depicts the anomalous difference Patterson maps at (a) 2.7 A and (b) at 2.3 ~ resolution.
Figure 9 depicts electron density maps of residues 76 to 82 from molecule 1 of S. aureus thymidylate kinase (SEQ ID NO:1) at (a) 2.7 ~ and (b) at 2.3 ~ resolution.
Figure 10 lists the structure factors and multiple anomalous dispersion phases for the crystal structure of S aureus thymidylate kinase (SEQ ID NO:1). "INDE" refers to the indices h, k, and 1 (columns 2, 3, and 4 respectively) of the lattice planes. "FOBS" refers to the structure factor (F) of the observed reflections. "SIGMA" is the standard deviation for the observations. "PHAS" refers to the phase used for the observations. "FOM"
refers to the figure of merit.
Figure 11 depicts a surface representation of a) E. coli TMK
with the inhibitor APST and b) S. aureus TMK with a hypothetical positioning of APST based on a structural alignment of Ca atoms from the E.
coli TMK + APST structure.
DETAILED DESCRIPTION OF THE INVENTION
Crystalline Forms) and Method of Making The three-dimensional structure of S. aureus thymidylate kinase was solved using high resolution x-ray crystallography to 2.3 ~
resolution (see Figure 2 and Example 1). Accordingly, the invention includes a TMK crystal and/or a crystal with TMK co-crystallized with a ligand, such as an inhibitor. Preferably, the crystal has trigonal space group symmetry P2~. More preferably, the crystal comprises rectangular shaped unit cells, each unit cell having dimensions of a, b, and c; wherein a is about 40 ~ to about 60 ~, b is about 80 ~ to about 100 ~, and c is about 40 ~ to about 60 ~; and wherein a = y = 90° and (3 is about 80° to about 120°. The crystallized enzyme is a dimer with a single dimer in the asymmetric unit.
Purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml may be crystallized, for example, by using a streak seeding procedure from a solution including about 5 wt. % to about 50 wt. % PEG (preferably having a number average molecular weight between about 200 and about 20,000), about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. Use of a buffer having a pKa of between about 5 and 8 is preferred. Molecular complexes of purified S.
aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml may also be crystallized, for example, from a solution including about 2 mM to about 20 mM (3,y-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7. A "molecular complex" means a protein in covalent or non-covalent association with a chemical entity. A buffer having a pKa of between about 5 and 8 is preferred for use in the crystallization method. A particularly preferred buffer is about 0.4M to about 2.0M sodium citrate. Variation in buffer and buffer pH as well as other additives such as PEG is apparent to those skilled in the art and may result in similar crystals.
The invention further includes an S. aureus thymidylate kinase crystal or S. aureus thymidylate kinase/ligand crystal that is isomorphous with an S. aureus thymidylate kinase crystal characterized by a unit cell having dimensions of a, b, and c; wherein a is about 40 t~ to about 60 fir, b is about 80 ~ to about 100 ~, and c is about 40 ~r to about 60 ~;
and wherein a = y = 90° and ~i is about 80° to about 120°.
X-ray C s~~tallo~raphic Analysis Each of the constituent amino acids of S. aureus thymidylate kinase is defined by a set of structure coordinates as set forth in Figure 2.
The term "structure coordinates" refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of an S.
aureus thymidylate kinase complex in crystal form. The diffraction data are used to calculate an electron density map of the repeating unit of the crystal.
The electron density maps are then used to establish the positions of the individual atoms of the S. aureus thymidylate kinase protein or protein/ligand complex.
Slight variations in structure coordinates can be generated by mathematically manipulating the S. aureus thymidylate kinase or S. aureus thymidylate kinase/ligand structure coordinates. For example, the structure coordinates set forth in Figure 2 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above. Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal, could also yield variations in structure coordinates. Such slight variations in the individual coordinates will have little effect on overall shape. If such variations are within an acceptable standard error as compared to the original coordinates, the resulting three-dimensional shape is considered to be structurally equivalent.
Structural equivalence is described in more detail below.
It should be noted that slight variations in individual structure coordinates of the S aureus thymidylate kinase would not be expected to significantly alter the nature of chemical entities such as ligands that could associate with the substrate binding pockets. In this context, the phrase "associating with" refers to a condition of proximity between a chemical entity, or portions thereof, and an S. aureus thymidylate kinase molecule or portions thereof. The association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent.
Thus, for example, a ligand that bound to a substrate binding pocket of S. aureus thymidylate kinase would also be expected to bind to or interfere with another substrate binding pocket whose structure coordinates define a shape that falls within the acceptable error.
It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus thymidylate kinase may be different than that of S aureus thymidylate kinase expressed in E.
coli.
Active Site and Other Structural Features Applicants' invention has provided, for the first time, information about the shape and structure of the substrate binding pockets of S. aureus thymidylate kinase. The structures of both the TMP and the TMP/ATP substrate binding pockets are elucidated. The secondary structure of the S. aureus thymidylate kinase monomer includes a five stranded parallel ~i sheet surrounded by nine a helices (Figure 3). This solved crystal structure of S. aureus thymidylate kinase does not contain any ligand which has resulted in a disordered loop between helices a7 and a8 (Figure 4). This loop has been called the "lid" in the structures of thymidylate kinase homologs from E. coli and S. cerevisiae. In E. coli the lid contains Arg 153 which is responsible for phosphate binding of the ATP
substrate as shown in the X-ray crystal structure of the E. coli enzyme with the APST inhibitor, a transition state analog of TMP/ATP (A. Lavie et al., Biochemistry 37:3677-86 (1998)). In contrast the analogous arginine in S.
cerevisiae comes from the P loop (Arg 15) between ail and al (A. Lavie et al., Proc. Natl. Acad. Sci. USA, 95:14045-SO (1998)). This distinction as further manifested in sequence differences between the P loop and lid regions has led to the classification of the S. cerevisiae enzyme as a class I
thymidylate kinase (which also includes human thymidylate kinase) and the E. coli enzyme as a class II thymidylate kinase (A. Lavie, Proc. Natl. Acad.
Sci. USA, 95:14045-50 (1998)). Fortunately, S. aureus (SEQ ID NO:1) has greater sequence similarity to the E. coli enzyme (SEQ ID N0:2, 38%
identical, 59% similar) than the S. cerevisiae enzyme (SEQ ID N0:3, 28%
identical, 46% similar) and contains 8148 in the lid region suggesting it should be classified as a class II thymidylate kinase (Figures S and 6). This classification suggests that it might be possible to design inhibitors that are specific for the S. aureus enzyme and not eukaryotic thymidylate kinases.
Superposition of the S aureus TMK with E. coli TMK gave a r.m.s. deviation of 2.19 ~ for analogous residues (Figure 5). Similarly, superposition of S. aureus TMK with S cerevisiae TMK gave a r.m.s.
deviation of 3.26 ~ (Figure 6). Analysis of the active site residues from E.
coli TMK as observed in the APST inhibitor complex shows at least eleven residues that make direct hydrogen bonds to the inhibitor and another six residues make water mediated or hydrophobic interactions. Analysis of the active site residues from S. aureus TMK sequence reveals strong conservation of these active site residues with the E. coli active site (Figure 7b); 15 of the 17 residues involved in the protein-inhibitor complex are identical while the two remaining residues are strongly conserved. An analogous comparison for the S. cerevisiae TMK (Figure 7b) shows only four of 18 residues conserved within the active site suggesting that specificity between the S. aureus and eukaryotic thymidylate kinases might be attainable.
Comparing the liganded E. coli TMK structure with the unliganded S. aureus structure, it is apparent that a significant movement of the main chain around the active site (e.g. helix a2 and helix a7) including the ordering of the disordered residues must occur upon ligand binding.
Figure 11 shows where the APST inhibitor would be expected in the S.
aureus TMK structure based on an alignment of the E. coli TMK-APST
inhibitor complex. There does appear to be a surface in the S. aureus TMK
structure which would complement the ATP and TMP substrates, although it is clear from this surface view that an important part of the structure, the lid, is missing from the S. aureus TMK structure. Figure 8 clearly illustrates the role for this portion of the protein in completing the active site and closing off the thymidylate moiety from solvent.
Binding pockets are of significant utility in fields such as drug discovery. The association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the binding pockets of receptors and enzymes. Such associations may occur with all or any parts of the binding pocket. An understanding of such associations helps lead to the design of drugs having more favorable associations with their target, and thus improved biological effects. Therefore, this information is valuable in designing potential inhibitors of S. aureus thymidylate kinase-like substrate binding pockets, as discussed in more detail below.
The term "binding pocket," as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity. Thus, a binding pocket may include or consist of features such as cavities, surfaces, or interfaces between domains. Chemical entities that may associate with a binding pocket include, but are not limited to, cofactors, substrates, inhibitors, agonists, and antagonists.
The amino acid constituents of an S. aureus thymidylate kinase substrate binding pocket as defined herein are positioned in three dimensions in accordance with the structure coordinates listed in Figure 2.
In one aspect, the structure coordinates defining a substrate binding pocket of S. aureus thymidylate kinase include structure coordinates of all atoms in the constituent amino acids; in another aspect, the structure coordinates of a substrate binding pocket include structure coordinates of just the backbone atoms of the constituent atoms.
The TMP substrate binding pocket of S. aureus thymidylate kinase preferably includes the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3, as represented by the structure coordinates listed in Figure 2.
Alternatively, the TMP substrate binding pocket of S. aureus thymidylate kinase may be defined by those amino acids whose backbone atoms are situated within about 3.5 t~, more preferably within about 5 ~, most preferably within about 7 A, of one or more constituent atoms of a bound substrate or inhibitor. In yet another alternative, the TMP substrate binding pocket may be defined by those amino acids whose backbone atoms are, situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Ser98, the sphere having a radius of about 10 ~, preferably about 15 ~, and more preferably about 20 ~.
The TMP/ATP substrate binding pocket of S. aureus thymidylate kinase preferably includes the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6, as represented by the structure coordinates listed in Figure 2. Alternatively, the TMP/ATP substrate binding pocket of S. aureus thyrnidylate kinase may be defined by those amino acids whose backbone atoms are situated within about 3.5 ~, more preferably within about 5 ~, most preferably within about 7 ~, of one or more constituent atoms of a bound substrate or inhibitor. In yet another alternative, the TMP/ATP substrate binding pocket may be defined by those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Arg93, the sphere having a radius of about 10 t~, preferably about 15 ~, and more preferably about 20 ~.
The term "S. aureus thymidylate kinase-like substrate binding pocket" refers to a portion of a molecule or molecular complex whose shape is sufficiently similar to at least a portion of a substrate binding pocket of S
aureus thymidylate kinase as to be expected to bind related TMP and/or ATP structural analogues. A structurally equivalent substrate binding pocket is defined by a root mean square deviation from the structure coordinates of the backbone atoms of the amino acids that make up substrate binding pockets in S. aureus thymidylate kinase (as set forth in Figure 2) of at most about 2.1 ~. How this calculation is obtained is described below.
Accordingly, the invention provides molecules or molecular complexes comprising an S. aureus thymidylate kinase substrate binding pocket or S aureus thyrnidylate kinase-like substrate binding pocket, as defined by the sets of structure coordinates described above.
Three-dimensional Configurations X-ray structure coordinates define a unique configuration of points in space. Those of skill in the art understand that a set of structure coordinates for protein or an protein/ligand complex, or a portion thereof, define a relative set of points that, in turn, define a configuration in three dimensions. A similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between coordinates remain essentially the same. In addition, a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.
The present invention thus includes the scalable three-dimensional configuration of points derived from the structure coordinates of at least a portion of an S. aureus thymidylate kinase molecule or molecular complex, as listed in Figure 2, as well as structurally equivalent configurations, as described below. Preferably, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of a plurality of the amino acids defining an S. aureus thymidylate kinase substrate binding pocket.
In one embodiment, the scalable three-dimensional configuration includes points derived from structure coordinates S representing the locations the backbone atoms of a plurality of amino acids defining the S. aureus thymidylate kinase TMP substrate binding pocket, preferably the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3.
Alternatively, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of the side chain and the backbone atoms (other than hydrogens) of a plurality of the amino acids defining the S. aureus thymidylate kinase TMP substrate binding pocket, preferably the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3.
In another embodiment, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations the backbone atoms of a plurality of amino acids defining the S. aureus thymidylate kinase TMP/ATP substrate binding pocket, preferably the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6. Alternatively, the scalable three-dimensional configuration includes points derived from structure coordinates representing the locations of the side chain and the backbone atoms (other than hydrogens) of a plurality of the amino acids defining the S. aureus thymidylate kinase TMP/ATP substrate binding pocket, preferably the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6.
Likewise, the invention also includes the scalable three-dimensional configuration of points derived from structure coordinates of molecules or molecular complexes that are structurally homologous to S.
aureus thymidylate kinase, as well as structurally equivalent configurations.
Structurally homologous molecules or molecular complexes are defined below. Advantageously, structurally homologous molecules can be identified using the structure coordinates of S. aureus thymidylate kinase according to a method of the invention.
The configurations of points in space derived from structure coordinates according to the invention can be visualized as, for example, a holographic image, a stereodiagram, a model or a computer-displayed image, and the invention thus includes such images, diagrams or models.
Structurally Eguivalent Crystal Structures Various computational analyses can be used to determine whether a molecule or a substrate binding pocket portion thereof is "structurally equivalent," defined in terms of its three-dimensional structure, to all or part of S aureus thymidylate kinase or its substrate binding pockets.
Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, CA) version 4.1, and as described in the accompanying User's Guide.
The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. The procedure used in Molecular Similarity to compare structures is divided into four steps: (1) load the structures to be compared; (2) define the atom equivalences in these structures; (3) perform a fitting operation; and (4) analyze the results.
Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, Ca, C, and O) for all conserved residues between the two structures being compared. A
conserved residue is defined as a residue which is structurally or functionally equivalent. Only rigid fitting operations are considered.
When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by QUANTA.
For the purpose of this invention, any molecule or molecular complex or substrate binding pocket thereof, or any portion thereof, that has a root mean square deviation of conserved residue backbone atoms (N, Ca, C, O) of less than about 2.1 t~, when superimposed on the relevant backbone atoms described by the reference structure coordinates listed in Figure 2, is considered "structurally equivalent" to the reference molecule. That is to say, the crystal structures of those portions of the two molecules are substantially identical, within acceptable error. Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates listed in Figure 2 ~ a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 t~. More preferably, the root mean square deviation is less than about 1.0 ~. Another embodiment of this invention is a molecular complex defined by the structure coordinates listed in Figure 2 for those amino acids listed in Table 1, ~ a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 ~, preferably less than about 1.0 ~ . Still another embodiment of this invention is a molecular complex defined by the structure coordinates listed in Figure 2 for those amino acids listed in Table 4, t a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.1 ~, preferably less than about 1.0 t~.
The term "root mean square deviation" means the square root of the arithmetic mean of the squares of the deviations. It is a way to express the deviation or variation from a trend or object. For purposes of this invention, the "root mean square deviation" defines the variation in the backbone of a protein from the backbone of S. aureus thymidylate kinase or a substrate binding pocket portion thereof, as defined by the structure coordinates of S. aureus thymidylate kinase described herein.
Machine Readable Stora~ye Media Transformation of the structure coordinates for all or a portion of S. aureus thymidylate kinase or the S. aureus thymidylate kinase/ligand complex or one of its substrate binding pockets, for structurally homologous molecules as defined below, or for the structural equivalents of any of these molecules or molecular complexes as defined above, into three-dimensional graphical representations of the molecule or complex can be conveniently achieved through the use of commercially-available software.
The invention thus further provides a machine-readable storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of any of the molecule or molecular complexes of this invention that have been described above. In a preferred embodiment, the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex comprising all or any parts of an S. aureus thymidylate kinase substrate binding pocket or an S. aureus thymidylate kinase-like substrate binding pocket, as defined above. In another preferred embodiment, the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of all of the amino acids listed in Figure 2, ~ a root mean square deviation from the backbone atoms of said amino acids of not more than 2.1 ~.
In an alternative embodiment, the machine-readable data storage medium comprises a data storage material encoded with a first set of machine readable data which comprises the Fourier transform of the structure coordinates set forth in Figure 2, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data comprising the x-ray diffraction pattern of a molecule or molecular complex to determine at least a portion of the structure coordinates corresponding to the second set of machine readable data.
For example, a system for reading a data storage medium may include a computer comprising a central processing unit ("CPU"), a working memory which may be, e.g., RAM (random access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube ("CRT") displays, light emitting diode ("LED") displays, liquid crystal displays ("LCDs"), electroluminescent displays, vacuum fluorescent displays, field emission displays ("FEDs"), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, track balls, touch pads, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus. The system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the Internet) to other systems (e.g., computers, hosts, servers, etc.). The system may also include additional computer controlled devices such as consumer electronics and appliances.
Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device.
Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices. By way of example, the output hardware may include a display device for displaying a graphical representation of a binding pocket of this invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.
In operation, a CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. References to components of the hardware system are included as appropriate throughout the following description of the data storage medium.
Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof. Examples of such data storage devices include, but are not limited to, hard disk devices, CD
devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device. It should be understood that these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.
Structurally Homologous Molecules, Molecular Completes, and Crystal Structures The structure coordinates set forth in Figure 2 can be used to aid in obtaining structural information about another crystallized molecule or molecular complex. The method of the invention allows determination of at least a portion of the three-dimensional structure of molecules or molecular complexes which contain one or more structural features that are similar to structural features of S. aureus thymidylate kinase, These molecules are referred to herein as "structurally homologous" to S. aureus thymidylate kinase, Similar structural features can include, for example, regions of amino acid identity, conserved active site or binding site motifs, and similarly arranged secondary structural elements (e.g., a helices and (3 sheets). Optionally, structural homology is determined by aligning the residues of the two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize-the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. Preferably, two amino acid sequences are compared using the Blastp program, version 2Ø9, of the BLAST 2 search algorithm, as described by Tatiana et al., FEMS
Microbiol Lett 174, 247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix =
BLOSUM62; open gap penalty =11, extension gap penalty = 1, gap x dropoff = 50, expect = 10, wordsize = 3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as "identity." Preferably, a structurally homologous molecule is a protein that has an amino acid sequence sharing at least 65%
identity with a native or recombinant amino acid sequence of S. aureus thymidylate kinase (for example, SEQ m NO:1 ). More preferably, a protein that is structurally homologous to S. aureus thymidylate kinase includes at least one contiguous stretch of at least 50 amino acids that shares at least 80% amino acid sequence identity with the analogous portion of the native or recombinant S. aureus thymidylate kinase (for example, SEQ ID NO:1).
Methods for generating structural information about the structurally homologous molecule or molecular complex are well-known and include, for example, molecular replacement techniques.
Therefore, in another embodiment this invention provides a method of utilizing molecular replacement to obtain structural information about a molecule or molecular complex whose structure is unknown comprising the steps of (a) crystallizing the molecule or molecular complex of unknown structure;
(b) generating an x-ray diffraction pattern from said crystallized molecule or molecular complex; and (c) applying at least a portion of the structure coordinates set forth in Figure 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of the molecule or molecular complex whose structure is unknown.
By using molecular replacement, all or part of the structure coordinates of S. aureus thyrnidylate kinase or the S. aureus thymidylate kinase/ligand complex as provided by this invention can be used to determine the structure of a crystallized molecule or molecular complex whose structure is unknown more quickly and efficiently than attempting to determine such information ab initio.
Molecular replacement provides an accurate estimation of the phases for an unknown structure. Phases are a factor in equations used to solve crystal structures that cannot be determined directly. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time-consuming process that involves iterative cycles of approximations and refinements and greatly hinders the solution of crystal structures. However, when the crystal structure of a protein containing at least a structurally homologous portion has been solved, the phases from the known structure provide a satisfactory estimate of the phases for the unknown structure.
Thus, this method involves generating a preliminary model of a molecule or molecular complex whose structure coordinates are unknown, by orienting and positioning the relevant portion of S. aureus thymidylate kinase or the S. aureus thymidylate kinase/ligand complex according to Figure 2 within the unit cell of the crystal of the unknown molecule or molecular complex so as best to account for the observed x-ray diffraction pattern of the crystal of the molecule or molecular complex whose structure is unknown. Phases can then be calculated from this model and combined with the observed x-ray diffraction pattern amplitudes to generate an electron density map of the structure whose coordinates are unknown. This, in turn, can be subj ected to any well-known model building and structure refinement techniques to provide a final, accurate structure of the unknown crystallized molecule or molecular complex (E. Lattman, "Use of the Rotation and Translation Functions," in Meth. E, 115, pp. 55-77 (1985); M.G. Rossman, ed., "The Molecular Replacement Method," Int. Sci.
Rev. Ser., No. 13, Gordon & Breach, New York (1972)).
Structural information about a portion of any crystallized molecule or molecular complex that is sufficiently structurally homologous to a portion of S. aureus thymidylate kinase can be resolved by this method.
In addition to a molecule that shares one or more structural features with S
aureus thymidylate kinase as described above, a molecule that has similar bioactivity, such as the same catalytic activity, substrate specificity or ligand binding activity as S. aureus thymidylate kinase, may also be sufficiently structurally homologous to S. aureus thyrnidylate kinase to permit use of the structure coordinates of S aureus thyrnidylate kinase to solve its crystal structure.
In a preferred embodiment, the method of molecular replacement is utilized to obtain structural information about a molecule or molecular complex, wherein the molecule or molecular complex comprises at least one S. aureus thymidylate kinase subunit or homolog. A "subunit"
of S. aureus thymidylate kinase is an S. aureus thymidylate kinase molecule that has been truncated at the N-terminus or the C-terminus, or both. In the context of the present invention, a "homolog" of S. aureus thymidylate kinase is a protein that contains one or more amino acid substitutions, deletions, additions, or rearrangements with respect to the amino acid sequence of S. aureus thymidylate kinase (SEQ m NO:1), but that, when folded into its native conformation, exhibits or is reasonably expected to exhibit at least a portion of the tertiary (three-dimensional) structure of S
aureus thymidylate kinase, For example, structurally homologous molecules can contain deletions or additions of one or more contiguous or noncontiguous amino acids, such as a loop or a domain. Structurally homologous molecules also include "modified" S. aureus thymidylate kinase molecules that have been chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- temninal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.
A heavy atom derivative of S. aureus thymidylate kinase is also included as an S. aureus thymidylate kinase homolog. The term "heavy atom derivative" refers to derivatives of S. aureus thyrnidylate kinase produced by chemically modifying a crystal of S.,aureus thymidylate kinase, In practice, a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thiomersal or uranyl acetate, which can diffuse through the crystal and bind to the surface of the protein. The locations) of the bound heavy metal atoms) can be determined by x-ray diffraction analysis of the soaked crystal. This information, in turn, is used to generate the phase information used to construct three-dimensional structure of the protein (T.L. Blundell and N.L. Johnson, Protein Cr~rstallogrraphy, Academic Press (1976)).
Because S. aureus thymidylate kinase can crystallize in more than one crystal form, the structure coordinates of S. aureus thymidylate kinase as provided by this invention are particularly useful in solving the structure of other crystal forms of S. aureus thymidylate kinase or S. aureus thymidylate kinase complexes.
The structure coordinates of S. aureus thymidylate kinase as provided by this invention are particularly useful in solving the structure of S. aureus thymidylate kinase mutants. Mutants may be prepared, for example, by expression of S. aureus thymidylate kinase cDNA previously altered in its coding sequence by oligonucleotide-directed mutagenesis.
Mutants may also be generated by site-specific incorporation of unnatural amino acids into thymidylate kinase proteins using the general biosynthetic method of C.J. Noren et al., Science, 244:182-188 (1989). In this method, the codon encoding the amino acid of interest in wild-type S aureus thymidylate kinase is replaced by a "blank" nonsense codon, TAG, using oligonucleotide-directed mutagenesis. A suppressor tRNA directed against this codon is then chemically aminoacylated in vitro with the desired unnatural amino acid. The aminoacylated tRNA is then added to an in. vitro translation system to yield a mutant S aureus thymidylate kinase with the site-specific incorporated unnatural amino acid.
Selenocysteine or selenomethionine may be incorporated into wild-type or mutant S. aureus thymidylate kinase by expression of S. aureus thymidylate kinase-encoding cDNAs in auxotrophic E. coli strains (W.A.
Hendrickson et al., EMBO J., 9(5):1665-1672 (1990)). In this method, the wild-type or mutagenized S. aureus thymidylate kinase cDNA may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both). Alternatively, selenomethionine analogues may be prepared by down regulation methionine biosynthesis. (T.E. Benson et al., Nat. Struct. Biol., 2:644-53 (1995); G.D. Van Duyne et al., J. Mol. Biol.
229:105-24 (1993)).
The structure coordinates of S. aureus thymidylate kinase listed in Figure 2 are also particularly useful to solve the structure of crystals of S. aureus thymidylate kinase, S. aureus thymidylate kinase mutants or S.
aureus thymidylate kinase homologs co-complexed with a variety of chemical entities. This approach enables the determination of the optimal sites for interaction between chemical entities, including candidate S. aureus thymidylate kinase inhibitors and S. aureus thymidylate kinase. Potential sites for modification within the various binding site of the molecule can also be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between S. aureus thymidylate kinase and a chemical entity. For example, high resolution x-ray diffraction data collected from crystals exposed to different types of solvent allows the determination of where each type of solvent molecule resides. Small molecules that bind tightly to those sites can then be designed and synthesized and tested for their S. aureus thymidylate kinase inhibition activity.
All of the complexes referred to above may be studied using well-known x-ray diffraction techniques and may be refined versus 1.5-3 ~
resolution x-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, 81992, distributed by Molecular Simulations, Inc.; see, e.g., Blundell & Johnson, supra; Meth.
Enz~ol., Vol. 114 & 115, H.W. Wyckoff et al., eds., Academic Press (1985)). This information may thus be used to optimize known S. aureus thymidylate kinase inhibitors, and more importantly, to design new S.
aureus thymidylate kinase inhibitors.
The invention also includes the unique three-dimensional configuration defined by a set of points defined by the structure coordinates for a molecule or molecular complex structurally homologous to S. aureus thymidylate kinase as determined using the method of the present invention, structurally equivalent configurations, and magnetic storage media comprising such set of structure coordinates.
Further, the invention includes structurally homologous molecules as identified using the method of the invention.
Homolo~w Modeling Using homology modeling, a computer model of an S aureus thymidylate kinase homolog can be built or refined without crystallizing the homolog. First, a preliminary model of the S. aureus thymidylate kinase homolog is created by sequence alignment with S aureus thymidylate kinase, secondary structure prediction, the screening of structural libraries, or any combination of those techniques. Computational software may be used to carry out the sequence alignments and the secondary structure predictions. Structural incoherences, e.g., structural fragments around insertions and deletions, can be modeled by screening a structural library for peptides of the desired length and with a suitable conformation. For prediction of the side chain conformation, a side chain rotamer library may be employed. If the S. aureus thymidylate kinase homolog has been crystallized, the final homology model can be used to solve the crystal structure of the homolog by molecular replacement, as described above.
Next, the preliminary model is subjected to energy minimization to yield an energy minimized model. The energy minimized model may contain regions where stereochemistry restraints are violated, in which case such regions are remodeled to obtain a final homology model. The homology model is positioned according to the results of molecular replacement, and subjected to further refinement comprising molecular dynamics calculations.
Rational Drug DesiEn Computational techniques can be used to screen, identify, select and/or design chemical entities capable of associating with S aureus thymidylate kinase or structurally homologous molecules. Knowledge of the structure coordinates for S. aureus thymidylate kinase permits the design and/or identification of synthetic compounds and/or other molecules which have a shape complementary to the conformation of the S. aureus thymidylate kinase binding site. In particular, computational techniques can be used to identify or design chemical entities, such as inhibitors, agonists and antagonists, that associate with an S aureus thymidylate kinase substrate binding pocket or an S. aureus thymidylate kinase-like substrate binding pocket. Inhibitors may bind to or interfere with all or a portion of an active site of S. aureus thymidylate kinase, and can be competitive, non-competitive, or uncompetitive inhibitors; or interfere with dimerization by binding at the interface between the two monomers. Once identified and screened for biological activity, these inhibitors/agonists/antagonists may be used therapeutically or prophylactically to block S. aureus thymidylate kinase activity and, thus, inhibit the growth of the bacteria or cause its death.
Structure-activity data for analogues of ligands that bind to or interfere with S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pockets can also be obtained computationally.
The term "chemical entity," as used herein, refers to chemical compounds, complexes of two or more chemical compounds, and fragments of such compounds or complexes. Chemical entities that are determined to associate with S. aureus thyrnidylate kinase are potential drug candidates.
Data stored in a machine-readable storage medium that is capable of displaying a graphical three-dimensional representation of the structure of S aureus thymidylate kinase or a structurally homologous molecule, as identified herein, or portions thereof may thus be advantageously used for drug discovery. The structure coordinates of the chemical entity are used to generate a three-dimensional image that. can be computationally fit to the three-dimensional image of S. aureus thymidylate kinase or a structurally homologous molecule. The three-dimensional molecular structure encoded by the data in the data storage medium can then be computationally evaluated for its ability to associate with chemical entities. When the molecular structures encoded by the data is displayed in a graphical three-dimensional representation on a computer screen, the protein structure can also be visually inspected for potential association with chemical entities.
One embodiment of the method of drug design involves evaluating the potential association of a known chemical entity with S
aureus thymidylate kinase or a structurally homologous molecule, particularly with an S. aureus thyrnidylate kinase substrate binding pocket or S. aureus thyrnidylate kinase-like substrate binding pocket. The method of drug design thus includes computationally evaluating the potential of a selected chemical entity to associate with any of the molecules or molecular complexes set forth above. 'This method comprises the steps of (a) employing computational means to perform a fitting operation between the selected chemical entity and a substrate binding pocket or a pocket nearby the substrate binding pocket of the molecule or molecular complex;
and (b) analyzing the results of said fitting operation to quantify the association between the chemical entity and the substrate binding pocket.
In another embodiment, the method of drug design involves computer-assisted design of chemical entities that associate with S. aureus thymidylate kinase, its homologs, or portions thereof. Chemical entities can be designed in a step-wise fashion, one fragment at a time, or may be designed as a whole or "de novo."
To be a viable drug candidate, the chemical entity identified or designed according to the method must be capable of structurally associating with at least part of an S. aureus thymidylate kinase or S aureus thymidylate kinase-like substrate binding pockets, and must be able, sterically and energetically, to assume a conformation that allows it to associate with the S. aureus thymidylate kinase or S. aureus thyrnidylate kinase-like substrate binding pocket. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions.
Conformational considerations include the overall three-dimensional structure and orientation of the chemical entity in relation to the substrate binding pocket, and the spacing between various functional groups of an entity that directly interact with the S. aureus thymidylate kinase-like substrate binding pocket or homologs thereof.
Optionally, the potential binding of a chemical entity to an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket is analyzed using computer modeling techniques prior to the actual synthesis and testing of the chemical entity. If these computational experiments suggest insufficient interaction and association between it and the S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket, testing of the entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to or interfere with an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. Binding assays to determine if a compound actually interferes with S. aureus thymidylate kinase can also be performed and are well known in the art. Binding assays may employ kinetic or thermodynamic methodology using a wide variety of techniques including, but not limited to, microcalorimetry, circular dichroism, capillary zone electrophoresis, nuclear magnetic resonance spectroscopy, fluorescence spectroscopy, and combinations thereof.
One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with an S.
aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. This process may begin by visual inspection of, for example, an S aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket on the computer screen based on the S. aureus thymidylate kinase structure coordinates listed in Figure 2 or other coordinates which define a similar shape generated from the machine-readable storage medium. Selected fragments or chemical entities may then be positioned in a variety of orientations, or docked, within the substrate binding pocket. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.
Specialized computer programs may also assist in the process of selecting fragments or chemical entities. Examples include GRID (P.J.
Goodford, J. Med. Chem. 28:849-857 (1985); available from Oxford University, Oxford, UK); MCSS (A. Miranker et al., Proteins: Struct. Funct.
Gen.,11:29-34 (1991); available from Molecular Simulations, San Diego, CA); AUTODOCK (D.S. Goodsell et al., Proteins: Struct. Funct. Genet.
8:195-202 (1990); available from Scripps Research Institute, La Jolla, CA);
and DOCK (LD. Kuntz et al., J. Mol. Biol. 161:269-288 (1982); available from University of California, San Francisco, CA).
Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or complex.
Assembly may be preceded by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure coordinates of S. aureus thymidylate kinase. This would be followed by manual model building using software such as QUANTA or SYBYL (Tripos Associates, St. Louis, MO).
Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include, without limitation, CAVEAT (P.A. Bartlett et al., in Molecular Recognition in Chemical and Biological Problems," Special Publ., Royal Chem. Soc., 78:182-196 (1989);
G. Lauri et al., J. Comput. Aided Mol. Des. 8:51-66 (1994); available from the University of California, Berkeley, CA); 3D database systems such as ISIS (available from MDL Information Systems, San Leandro, CA;
reviewed in Y.C. Martin, J. Med. Chem. 35:2145-2154 (1992)); and HOOK
(M.B. Eisen et al., Proteins: Struc., Funct., Genet. 19:199-221 (1994);
available from Molecular Simulations, San Diego, CA).
S. aureus thymidylate kinase binding compounds may be designed "de novo" using either an empty binding site or optionally including some portions) of a known inhibitor(s). There are many de novo ligand design methods including, without limitation, LUDI (H.-J. Bohm, J.
Comp. Aid. Molec. Design. 6:61-78 (1992); available from Molecular Simulations Inc., San Diego, CA); LEGEND (Y. Nishibata et al., Tetrahedron, 47:8985 (1991); available from Molecular Simulations Inc., San Diego, CA); LeapFrog (available from Tripos Associates, St. Louis, MO); and SPROUT (V. Gillet et al., J. Comput. Aided Mol. Design 7:127-153 (1993); available from the University of Leeds, UK).
Once a compound has been designed or selected by the above methods, the efficiency with which that entity may bind to or interfere with an S aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket may be tested and optimized by computational evaluation. For example, an effective S. aureus thymidylate kinase or S.
aureus thymidylate kinase-like substrate binding pocket inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding). Thus, the most efficient S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole;
more preferably, not greater than 7 kcal/mole. S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket inhibitors may interact with the substrate binding pocket in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free entity and the average energy of the conformations observed when the inhibitor binds to the protein.
An entity designed or selected as binding to or interfering with an S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme and with the surrounding water molecules. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole, and charge-dipole interactions.
Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interactions. Examples of programs designed for such uses include: Gaussian 94, revision C (M.J.
Frisch, Gaussian, Inc., Pittsburgh, PA 81995); AMBER, version 4.1 (P.A.
Kollman, University of California at San Francisco, 81995);
QUANTA/CHARMM (Molecular Simulations, Inc., San Diego, CA 81995);
Insight II/Discover (Molecular Simulations, Inc., San Diego, CA 81995);
Delphi (Molecular Simulations, Inc., San Diego, CA 81995); and AMSOL
(Quantum Chemistry Program Exchange, Indiana University). These programs may be implemented, for instance, using a Silicon Graphics workstation such as an Indigo2 with "IIVVIPACT" graphics. Other hardware systems and software packages will be known to those skilled in the art.
Another approach encompassed by this invention is the computational screening of small molecule databases for chemical entities or compounds that can bind in whole, or in part, to a S. aureus thymidylate kinase or S. aureus thymidylate kinase-like substrate binding pocket. In this screening, the quality of fit of such entities to the binding site may be judged either by shape complementarity or by estimated interaction energy (E.C.
Meng et al., J. Comp. Chem., 13, pp. 505-524 (1992)).
This invention also enables the development of chemical entities that can isomerize to short-lived reaction intermediates in the chemical reaction of a substrate or other compound that interferes with or with S. aureus thymidylate kinase. Time-dependent analysis of structural changes in S. aureus thymidylate kinase during its interaction with other molecules is carned out. The reaction intermediates of S. aureus thymidylate kinase can also be deduced from the reaction product in co-complex with S. aureus thymidylate kinase. Such information is useful to design improved analogues of known S. aureus thymidylate kinase inhibitors or to design novel classes of inhibitors based on the reaction intermediates of the S. aureus thymidylate kinase and inhibitor co-complex.
This provides a novel route for designing S. aureus thymidylate kinase inhibitors with both high specificity and stability.
Yet another approach to rational drug design involves probing the S aureus thymidylate kinase crystal of the invention with molecules comprising a variety of different functional groups to determine optimal sites for interaction between candidate S. aureus thymidylate kinase inhibitors and the protein. For example, high resolution x-ray diffraction data collected from crystals soaked in or co-crystallized with other molecules allows the determination of where each type of solvent molecule sticks. Molecules that bind tightly to those sites can then be further modified and synthesized and tested for their thymidylate kinase inhibitor activity (J. Travis, Science, 262:1374 (1993)).
1n a related approach, iterative drug design is used to identify inhibitors of S aureus thymidylate kinase. Iterative drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional structures of successive sets of protein/compound complexes. In iterative drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional structures of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex. This is accomplished by selecting compounds with inhibitory activity, obtaining crystals of this new protein/compound complex, solving the three dimensional structure of the complex, and comparing the associations between the new protein/compound complex and previously solved protein/compound complexes. By observing how changes in the compound affected the protein/compound associations, these associations may be optimized.
A compound that is identified or designed as a result of any of these methods can be obtained (or synthesized) and tested for its .
biological activity, e.g., inhibition of thymidylate kinase activity.
Pharmaceutical Compositions Inhibitors) Pharmaceutical compositions of this invention comprise an inhibitor of S. aureus TMK activity identified according to the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable Garner, adjuvant, or vehicle. The term "pharmaceutically acceptable carrier" refers to a carriers) that is "acceptable" in the sense of being compatible with the other ingredients of a.composition and not deleterious to the recipient thereof. Optionally, the pH of the formulation is adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability of the formulated compound or its delivery form.
Methods of making and using such pharmaceutical compositions are also included in the invention. The pharmaceutical compositions of the invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration or administration by injection is preferred. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, infra-articular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.
Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the S. aureus TMK inhibitory compounds described herein are useful for the prevention and treatment of S. aureus TMK mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the Garner materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80%
active compound.
In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1: Analysis of the Structure of S. aureus Th~ylate Kinase A. Expression, Purification and Crystallization The M15-1C Escherichia coli construct expressing S. aureus thymidylate kinase was obtained as a strain in which the Qiagen pREP4 vector was replaced with pREP4UX. Genes and polypeptides derived from S aureus, including S. aureus and thymidylate kinase, are published in EP
786519 A2 and WO 0012678, both assigned to Human Genome Sciences.
This plasmid contains the argU gene which codes for the AGA tRNA and prevents the lysine for arginine substitution which occurred in the original construct from Human Genome Sciences. For preparation of the selenomethionine analogue of thymidylate kinase, the construct was grown in a minimal salts medium, M9, which contained glucose and NH4C1 as the sources of carbon and nitrogen. Endogenous methionine biosynthesis was then inhibited while adding an excess of selenomethionine to the growth medium just prior to IPTG induction of thymidylate kinase synthesis (T.E.
Benson et al., Nat. Struct. Biol., 2:644-53 (1995); G.D. Van Duyne et al., J.
Mol. Biol. 229:105-24 (1993)). The formulation of basal M9 was Na2HP04, 6 g; KH2PO4, 3 g; NH4Cl, 1.0 g; and NaCI, 0.5 g per L of deionized water.
T'he pH was adjusted to 7.4 with concentrated KOH and the medium was sterilized by autoclaving. Prior to inoculation, the following filter sterilized solutions were added per L of basal medium: 1M MgS04, 1.0 mL; 1M
CaCl2, 0.1 mL; trace metal salts solution, 0.1 mL, 10 mM thiamin, 1.0 mL;
and 20% glucose, 20 mL. The trace metal salts solution contained per L of deionized water: MgC12~6H20, 39.44 g; MnS04~H20, 5.58 g; FeS04~7H20, 1.11 g; NaZMo04~2H20, 0.48 g; CaCl2, 0.33 g; NaCI, 0.12 g; and ascorbic acid, 1.0 g. Filter sterilized ampicillin and kanamycin were added to the medium at final concentrations of 100 mg/mL and 30mg/mL, respectively.
Fermentations were prepared in 100 mL volumes of M9 medium contained in 500 mL wide mouth flasks. A 0.1 mL aliquot of the stock culture was inoculated into the medium and allowed to grow at 30°C
for 18 - 20 hours with a shaking rate of 200 rpm. The seed culture was harvested by centrifugation and then resuspended in an equal volume of M9 medium. The resuspended seed was used to inoculate expression fermentations at a rate of 3%. For expression, the culture was grown under the same conditions to an A600 of ~0.6. At this point, methionine biosynthesis was down regulated by the addition of L-lysine, L-threonine, and L-phenylalanine at a final concentration for each of 100 mg/mL and L-leucine, L-isoleucine, and L-valine at 50 mg/mL each.
D,L-selenomethionine was added simultaneously to a final concentration of 100 mg/mL. After 15 - 20 minutes, expression of thyrnidylate kinase was induced by addition of IPTG (isopropyl thio-(3-D-galactosidase, Gibco BRL) to 1 mM. Growth of the culture was continued for an additional 3.5 hours until an A600 of 1.5 - 1.6. Cells were then harvested by centrifugation and frozen at -80°C. Under these conditions, the average yield of cell paste was 3.0 to 3.5 g/L.
For protein purification, all buffers were chilled to 4°C prior to use and all procedures were performed at 4°C. Cells (24.8 g wet weight) were resuspended in 125 mL of lysis buffer (25 mM Tris (pH 7.8), 500 mM
NaCI, 10% glycerol, 25 mM imidazole, 5 mM 2-mercaptoethanol, 0.2 mg/mL DNAse I) and ruptured by using an American Instrument French Press at 16,000 PSI. The lysate was clarified by centrifugation at 39,200 X g for 60 minutes in a JA20 rotor. The supernatant was filtered by using a Nalgene 0.2 ~m filter unit. The filtered supernatant was applied at 74 cm/hr to a Qiagen NTA Superflow column (1.6 cm i.d. X 11 cm (CV = 22 mL)) charged with nickel that was pre-equilibrated with EQ buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10% glycerol, 25 mM imidazole, 5 mM
2-mercaptoethanol). The column was washed with 7.7 CV of EQ buffer, 12.5 CV of wash buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10%
glycerol, 50 mM imidazole, 5 mM 2-mercaptoethanol) and eluted with 1.4 CV of elution buffer (25 mM Tris (pH 7.8), 500 mM NaCI, 10% glycerol, 300 mM imidazole, 5 mM 2-mercaptoethanol). During the elution the linear velocity was decreased to 42 cm/hr. The eluted fraction was treated with DTT to achieve a final concentration of 10 mM and dialyzed extensively against nitrogen sparged dialysis buffer (25 mM Tris (pH 7.8), 500 mM
NaCI, 10% glycerol, 10 mM DTT, pH 7.8).
The Mono Q analytical run was performed using 50 mL
native TMK (14 mg/mL) diluted to 200 mL with 20 mM Tris (pH 8.0). The sample was loaded onto a Mono Q (Amersham Pharmacia Biotech) column equilibrated with 20 mM Tris (pH 8.0) and run through a 20-40% (20 mM
Tris (pH 8.0) + 1.0M NaCI) gradient in 40 mL with a flow rate of 1.0 mL/min. The Mono P column run was performed using 50 mL TMK
(l4mg/mL) diluted to 200 mL with 25 mM bis-Tris (pH 6.71). The sample was injected onto a Mono P column (Amersham Pharmacia Biotech) equilibrated with 25 mM bis-Tris (pH 6.71 ) and run through a step gradient of 0-100-0 % Polybuffer Mix 96/74 (20:1), pH 5.80. Gel filtration studies were carried out on a Superose 200 column with a 500 mL sample of thymidylate kinase at a concentration of 4.2 mg/mL using 50 mM Tris (pH
8.5), 500 mM NaCI, 5 mM 2-mercaptoethanol, and 0.5% glycerol at a flow rate of 1 mL/min. For dynamic light scattering experiments, samples were mixed in 1.5m1 eppendorf tubes, then sterile filtered through a 0.22 mm ceramic membrane (Whatman). 20 mL of solution is read in a quartz cuvette in a Dyna Pro Molecular Sizing Instrument (Protein Solutions, Inc., Charlottesville, VA).
The native protein was exchanged into 50 mM Tris (pH 7.8), 5 mM 2-mercaptoethanol to a concentration of 15 mg/mL and screened for crystallization conditions using Crystal Screen I, Crystal Screen II, and MembFac Screen (Hampton Research, Laguna Niguel, CA). The most encouraging lead was from Hampton Crystal Screen I condition 23: 30%
PEG 400, O.1M Na HEPES pH 7.5, 0.2M MgCl2. Follow up screens indicated that PIPES buffer was most conducive to crystal formation.
The initial crystals of the thymidylate kinase were stacks of small plates that were inseparable and unusable for diffraction studies.
Biochemical analysis of the protein revealed that the sample was substantially pure by sodium dodecylsulfate polyacrylamide-gel electrophoresis (SDS-PAGE) analysis, but isoelectric focusing (IEF) gels revealed at least two distinct isoelectric species. It is likely, although yet unproven, that these isoelectric species were the cause of the morphology of the thymidylate kinase crystals. Further efforts at purification with a Mono Q column indicated that separation of these species would be difficult and it was not clear that large scale isoelectrofocusing using a Mono P column or preparative isoelectric focusing would improve the separation because of the small differences in pI. A series experiments exploring the feasibility of preparative isoelectric focusing experiments using PrIME (preparative isoelectric membrane electrophoresis) was hampered due to precipitation of the protein near its pI. Gel filtration did reveal that thymidylate kinase behaves as a dimer in solution, confirming earlier literature reports for the related E coli and yeast TMK. The initial crystallization conditions S contained 200 mM MgCl2 and later experiments showed that at least 150 mM MgCl2 was required for crystal formation. Dynamic light scattering experiments in the presence of MgCl2 revealed an interesting phenomenon where protein aggregation was reduced in the presence of MgCl2 over a number of hours leading to a monodisperse, dimeric sample suitable for crystallization.
The stacked plates were eventually transformed into single crystals through iterative streak seeding and crystallization on hanging or sitting drops with thymidylate kinase in 0.1 M PIPES (pH 6.6), 14-19% PEG
400, 0.2 M MgCl2. This technique involved taking the multinucleated crystals, crushing them into microcrystals, and using a dilution series of this suspension of microcrystals for seeding. It was observed that this second round of crystals were usually less multinucleated than when crystal formation was allowed to proceed via spontaneous nucleation. A second round of streak seeding was usually necessary in order to obtain multiple single crystals. Refinement of the streak seeding technique resulted in native and selenomethionine TMK crystals on the order of about 100 ~m x about 100 ~m x about 20 Vim.
Subsequent crystallization experiments also indicated that a protein concentration of 7 mg/mL was able to yield suitable crystals. The crystallization solution was a cryoprotective agent making it straightforward to freeze the crystals in liquid nitrogen for data collection.
Selenomethionine thymidylate kinase was exchanged into 10 mM Tris (pH
7.8), 10 mM DTT and concentrated to 7 or 14 mg/mL for crystallization experiments.
B. X-ray Diffraction Characterization Thymidylate kinase crystals were generally too small for useful data collection using standard x-ray diffraction equipment.
Therefore, all data collection was carried out at the Advanced Photon Source (Argonne, IL). The structure of S aureus thymidylate kinase was determined by multiple anomalous dispersion (MAD) using synchrotron radiation. Crystals were of the space group P21 with cell constants a = 49.8 A, b = 90.1 ~, c= 46.5 ~, a~y=90° and ~3 = 101.8°. The Matthews coefficient for these crystals assuming that there are two molecules in the asymmetric unit is 2.1 ~/Da with 40% solvent. Two MAD data sets were collected B one at 2.7 ~ and one at 2.3 ~.
Two selenomethionine multiple anomalous dispersion (MAD) experiments were performed (2.7~ resolution and 2.3 ~ resolution) using three different wavelengths (remote wavelength 1.0332 ~, 12000 eV, inflection point wavelength 0.979746 ~, 12654.8 eV, and the peak wavelength 0.979617 ~, 12656.5 eV).
C. Heavy Atom Derivative Selenomethionine thymidylate kinase was expressed using downregulation of methionine biosynthesis (T.E. Benson et al., Nat. Struct.
Biol., 2:644-53 (1995); G.D. Van Duyne et al., J. Mol. Biol. 229:105-24 (1993)) and purified in order to obtain de novo phases by multiple anomalous dispersion (W.A. Hendrickson, Science 254:51-8 (1991)).
Anomalous difference Patterson maps revealed six selenium sites (three for each of the two monomers in the asymmetric unit) (Figure 9). Patterson maps at 2.7 ~ showed that the atomic positions for the seleniums were not well resolved, but maps at 2.31 clearly defined the atomic positions of the heavy atoms. Unfortunately, the MAD phases for data collected at 2.3 ~
were of lower quality than the phases at 2.7 A, so initial model building was performed using the MAD phased map to 2.7 ~ (Figure 10). Subsequent refinement was conducted against the 2.3 ~ data, and this higher resolution structure is the one reported here.
D. Phase Combination Each of these individual data sets was indexed and integrated separately (see Tables 7 and 8 for integration statistics). The data sets were scaled to each other using the program SCALEIT in the CCP4 Program Suite (Collaborative Computational Project N4, Acta Cr ~~st. D50:760-3 (1994)). Patterson maps revealed six selenium sites (three for each monomer in the asymmetric unit) whose locations were determined by direct methods using SHELX (G.M. Sheldrick & R.O. Gould, Acta Cr ~~st.
B51:423-31 (1995)). Heavy atom refinement and phase calculations were conducted using SHARP (E. La Fortelle et al., A Maximum-Likelihood Heavy-Atom Parameter Refinement and Phasing Program for the M1R and MAD Methods, P. Bourne & K. Watenpaugh, eds., C .r~tallog_raphic Computing 7 (1997)). Phases calculated in SHARP were solvent flattened using the program SOLOMON (Collaborative Computational Project N4, Acta Cryst. D50:760-3 (1994)) and gave a significantly improved electron density map.
Table 7. Data collection and phasing statistics for structure of S. aureus TMK
~, 1.0332 ~ ~, 0.9797461 ~, 0.979617 ~
(12000 eV) (12654.8 eV) (12656.5 eV) Resolution 2.7 ~ 2.7 ~ 2.7 ~
No. observations76,132 62,273 76,145 No. unique 10,901 10,941 10,928 refl.
completeness 100% 100% 100%
RS~,I" 0.085 0.103 0.106 R~"u;s acentrics -- 0.61 0.67 R.~"u;~ anomalous 0.98 0.78 0.69 Phasing power centrics -- 1.28 1.21 acentrics -- 2.30 1.83 Mean figure of merit (to 2.7 ~ resolution) before solvent flattening 0.51 after solvent flattening 0.94 Table 8. Data collection and phasing statistics for structure of S. aureus TMK
~, 1.0332 t~ ~, 0.979746 ~ ~, 0.979617 A
(12000 eV) (12654.8 eV) (12656.5 eV) Resolution 2.3 ~ 2.3 ~ 2.3 ~
No. Observations76,712 123,553 123,372 No. unique 17,661 17,887 17,991 refl.
completeness 98.2% 99.4% 99.3%
Rsyr, 0.083 0.107 0.099 R~"u;~ acentrics -- 0.56 0.61 R~"";S anomalous 0.99 0.69 0.70 Phasing power centrics -- 1.34 1.38 acentrics -- 2.22 2.04 Mean figure of merit (to 2.3 ~ resolution) before solvent flattening 0.57 after solvent flattening 0.87 E. Model Building and Refinement At this stage in the structure solution, the coordinates for E.
coli thymidylate kinase greatly aided the process of model building for placement of the main chain backbone. Model building was done using the program CHAIN (J.S. Sack, Journal of Molecular Graphics 6:224-5 (1988)) and LORE (B.C. Finzel, Meth. Enz~. 277:230-42 (1997)). Refinement was carried out with XPLOR98 (A.T. Brunger, X-PLOR version 3.1: A
system for X-ray Crystallography and NMR, New Haven: Yale Univ. Press, (1992)) incorporating bulk solvent correction during the refinement (J.S.
Jiang & A.T. Brunger, J. Mol. Biol. 243:100-15 (1994)). Progress of the refinement was monitored by a decrease in both the R-factor and Free R-factor.
Table 9. Refinement Statistics for structure of S. aureus TMK
R-factor Free R-factor No. of reflections 20-2.3 ~ F> 2a 0.2366 0.3084 15,908 Bonds (t~) Angles(°) r.m.s deviation from ideal geometry 0.008 1.32 Number of atoms Average B-factor Protein 2978 27.2 Waters 174 3 8.9 Total 3152 27.81 Stereochemistry of the model was checked using PROCHECK (R.A. Laskowski et al., J. Appl. Cryst. 26:283-91 (1993)) revealing no residues in disallowed regions of the Ramachandran plot.
Figure 9 was made using SETOR (S.V. Evans, J. Mol. Graphics 11:134-8 (1993)) and Figures 3a, 4 were produced in MOLSCRIPT (P. Kraulis, J.
Appl. Cr ~~st. 24:946-50 (1991)) and Raster 3D (E.A. Merritt & M.E.P.
Murphy, Acta Cr~rst. D50:869-73 (1994)) while Figures Sa and 6a were produced in MOLSCRIPT (P. Kraulis, J. Ap~l. Cr ~~st. 24:946-50 (1991)) alone.
F. Assays.
Binding assays to determine if a compound actually interferes with S. aureus thymidylate kinase can also be performed. For example, thymidylate kinase activity can be measured by coupling the formation of ADP and TDP to the reactions catalyzed by PD, LDH, and NDP-Kinase, as shown below. Oxidation of NADH is accompanied by a decrease in absorbance at 340 nm, which is measured spectrophotometrically.
1 ) ATP + TMP T~'S'""d~~e K'"ase ~ ADp + TDP
2) ATP + TDP ~P~K"'~e , ADP + TTP
3) 2 ADP + 2 PEP PK 2 ATP + 2 PYRUVATE
4) 2 PYRUVATE + 2 NADH LDH 2 LACTATE +
2 NAD+
The standard reaction conditions employed during the kinetic characterization of the enzyme were: 50 mM HEPES, pH 8.0, 50 mM KCI, 2 mM MgClz, 4 U/ml PK, 5 U/ml LDH, 2 mM PEP, 1.5 mM ATP, 5 U/ml NDP-Kinase, 1.0 mM TMP, 0.22 mM NADH, and 0.8 ~g/ml T. kinase. All of the reagents except the T. Kinase were added to a cuvette and mixed, and the mixture was incubated at 24.5°C for 2 minutes. To start the reaction, the T. Kinase was added, the contents of the cuvette were mixed, and the decrease in absorbance at 340 nm was monitored for 4-5 minutes.
SEQUENCE LISTING FREE TEXT
SEQ ID NO:1 recombinant S. aureus thymidylate kinase (with polyhistidine [His6] sequence tag) SEQ ID N0:2 E coli thymidylate kinase SEQ ID N0:3 S. cerevisiae thymidylate kinase SEQUENCE LISTING
<110> Pharmacia & Upjohn <120> Crystallization and Structure Determination of Staphylococcus Aureus Thymidylate Kinase <130> 6245.PCP
<140> Unassigned <141> 2000-08-04 <150> 60/147,117 <151> 1999-08-04 <160> 3 <170> PatentIn Ver. 2.1 <210> 1 <211> 214 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Recombinant Staphylococcus aureus thymidylate kinase with 6-His tag <400> 1 Met Gly Ser Ala Phe Ile Thr Phe Glu Gly Pro Glu Gly Ser Gly Lys Thr Thr Val Ile Asn Glu Val Tyr His Arg Leu Val Lys Asp Tyr Asp Val Ile Met Thr Arg Glu Pro Gly Gly Val Pro Thr Gly Glu Glu Ile Arg Lys Ile Val Leu Glu Gly Asn Asp Met Asp Ile Arg Thr Glu Ala Met Leu Phe Ala Ala Ser Arg Arg Glu His Leu Val Leu Lys Val Ile Pro Ala Leu Lys Glu Gly Lys Val Val Leu Cys Asp Arg Tyr 11e Asp SUBSTITUTE SHEET (RULE 26) Ser Ser Leu Ala Tyr Gln Gly Tyr Ala Arg Gly Ile Gly Val Glu Glu Val Arg Ala Leu Asn Glu Phe Ala Ile Asn Gly Leu Tyr Pro Asp Leu Thr Ile Tyr Leu Asn Val Ser Ala Glu Val Gly Arg Glu Arg Ile Ile Lys Asn Ser Arg Asp Gln Asn Arg Leu Asp Gln Glu Asp Leu Lys Phe His Glu Lys Val Ile Glu Gly Tyr Gln Glu Ile Ile~His Asn Glu Ser Gln Arg Phe Lys Ser Val Asn Ala Asp Gln Pro Leu Glu Asn Val Val Glu Asp Thr Tyr Gln Thr Ile Ile Lys Tyr Leu Glu Lys Ile Arg Ser His His His His His His <210> 2 <211> 213 <212> PRT
<213> Escherichia coli <400> 2 Met Arg Ser Lys Tyr Ile Val Ile Glu Gly Leu Glu Gly Ala Gly Lys Thr Thr Ala Arg Asn Val Val Val Glu Thr Leu Glu Gln Leu Gly Ile Arg Asp Met Val Phe Thr Arg Glu Pro Gly Gly Thr Gln Leu Ala Glu Lys Leu Arg Ser Leu Val Leu Asp Ile Lys Ser Val Gly Asp Glu Val Ile Thr Asp Lys Ala Glu Val Leu Met Phe Tyr Ala Ala Arg Val Gln Leu Val Glu Thr Val Ile Lys Pro Ala Leu Ala Asn Gly Thr Trp Val SUBSTITUTE SHEET (RULE 26) Ile Gly Asp Arg His Asp Leu Ser Thr Gln Ala Tyr Gln Gly Gly Gly Arg Gly Ile Asp Gln His Met Leu Ala Thr Leu Arg Asp Ala Val Leu Gly Asp Phe Arg Pro Asp Leu Thr Leu Tyr Leu Asp Val Thr Pro Glu Val Gly Leu Lys Arg Ala Arg Ala Arg Gly Glu Leu Asp Arg Ile Glu 145 150 . 155 160 Gln Glu Ser Phe Asp Phe Phe Asn Arg Thr Arg Ala Arg Tyr Leu Glu Leu Ala Ala Gln Asp Lys Ser Ile His.Thr Ile Asp Ala Thr Gln Pro Leu Glu Ala Val Met Asp Ala Ile Arg Thr Thr Val Thr His Trp Val Lys Glu Leu Asp Ala <210> 3 <211> 216 <212> PRT
<213> Saccharomyces cerevisiae <400> 3 Met Met Gly Arg Gly Lys Leu Ile Leu Ile Glu Gly Leu Asp Arg Thr Gly Lys Thr Thr Gln Cys Asn Ile Leu Tyr Lys Lys Leu Gln Pro Asn Cys Lys Leu Leu Lys Phe Pro Glu Arg Ser Thr Arg Ile Gly Gly Leu Ile Asn Glu Tyr Leu Thr Asp Asp Ser Phe Gln Leu Ser Asp Gln Ala Ile His Leu Leu Phe Ser Ala Asn Arg Trp Glu Ile Val Asp Lys Ile Lys Lys Asp Leu Leu Glu Gly Lys Asn Ile Val Met Asp Arg Tyr Val SUBSTITUTE SHEET (RULE 26) Tyr Ser Gly Val Ala Tyr Ser Ala Ala Lys Gly Thr Asn Gly Met Asp Leu Asp Trp Cys Leu Gln Pro Asp Val Gly Leu Leu Lys Pro Asp Leu Thr Leu Phe Leu Ser Thr Gln Asp Val Asp Asn Asn Ala Glu Lys Ser Gly Phe Gly Asp Glu Arg Tyr Glu Thr Val Lys Phe Gln Glu Lys Val 145 150 155 ' 160 Lys Gln Thr Phe Met Lys Leu Leu Asp Lys Glu Ile Arg Lys Gly Asp Glu Ser Ile Thr Ile Val Asp Val Thr~Asn Lys Gly Ile Gln Glu Val Glu Ala Leu Ile Trp Gln Ile Val Glu Pro Val Leu Ser Thr His Ile Asp His Asp Lys Phe Ser Phe Phe SUBSTITUTE SHEET (RULE 26)
Claims (54)
1. A molecule or molecular complex comprising at least a portion of an S.
aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, wherein the TMP binding pocket comprises the amino acids listed in Table 1, the TMP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by the structure coordinates listed in Figure 2.
aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, wherein the TMP binding pocket comprises the amino acids listed in Table 1, the TMP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by the structure coordinates listed in Figure 2.
2. The molecule or molecular complex of claim 1, wherein the TMP binding pocket comprises the amino acids listed in Table 2.
3. The molecule or molecular complex of claim 1, wherein the TMP
binding pocket comprises the amino acids listed in Table 3.
binding pocket comprises the amino acids listed in Table 3.
4. A molecule or molecular complex comprising at least a portion of an S.
aureus thymidylate kinase TMP/ATP substrate binding pocket, wherein the TMP substrate binding pocket comprises the amino acids listed in Table 4, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by the structure coordinates listed in Figure 2.
aureus thymidylate kinase TMP/ATP substrate binding pocket, wherein the TMP substrate binding pocket comprises the amino acids listed in Table 4, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by the structure coordinates listed in Figure 2.
5. The molecule or molecular complex of claim 4, wherein the TMP/ATP
binding pocket comprises the amino acids listed in Table 5.
binding pocket comprises the amino acids listed in Table 5.
6. The molecule or molecular complex of claim 4, wherein the TMP/ATP
binding pocket comprises the amino acids listed in Table 6.
binding pocket comprises the amino acids listed in Table 6.
7. A molecule or molecular complex that is structurally homologous to an S. aureus kinase molecule or molecular complex, wherein the S.
aureus kinase molecule or molecular complex is represented by at least a portion of the structure coordinates listed in Figure 2.
aureus kinase molecule or molecular complex is represented by at least a portion of the structure coordinates listed in Figure 2.
8. A scalable three dimensional configuration of points, at least a portion of said points derived from structure coordinates of at least a portion of an S.
aureus kinase molecule or molecular complex listed in Figure 2 comprising at least one of an S. aureus kinase or kinase-like TMP or TMP/ATP binding pocket.
aureus kinase molecule or molecular complex listed in Figure 2 comprising at least one of an S. aureus kinase or kinase-like TMP or TMP/ATP binding pocket.
9. The scalable three dimensional configuration of points of claim 8, wherein substantially all of said points are derived from structure coordinates of an S. aureus kinase molecule or molecular complex listed in Figure 2.
10. The scalable three dimensional configuration of points of claim 8 wherein at least a portion of the points derived from the S. aureus kinase structure coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of amino acids defining an S. aureus kinase TMP binding pocket, the TMP binding pocket comprising the amino acids listed in Table 1.
11. The scalable three dimensional configuration of points of claim 10, wherein the TMP binding pocket comprises the amino acids listed in Table 2.
12. The scalable three dimensional configuration of points of claim 10, wherein the TMP binding pocket comprises the amino acids listed in Table 3.
13. The scalable three dimensional configuration of points of claim 8 wherein at least a portion of the points derived from the S. aureus thymidylate kinase structure coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of amino acids defining an S. aureus thymidylate kinase TMP/ATP binding pocket, the TMP/ATP substrate binding pocket comprising the amino acids listed in Table 4.
14. The scalable three dimensional configuration of points of claim 13, wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 5.
15. The scalable three dimensional configuration of points of claim 13, wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 6.
16. The scalable three dimensional configuration of points of claim 8 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image.
17. A scalable three dimensional configuration of points, at least a portion of the points derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S.
aureus thymidylate kinase molecule or molecular complex and comprises at least one of an S. aureus thyrnidylate kinase or thymidylate kinase-like TMP
or TMP/ATP binding pocket.
aureus thymidylate kinase molecule or molecular complex and comprises at least one of an S. aureus thyrnidylate kinase or thymidylate kinase-like TMP
or TMP/ATP binding pocket.
18. The scalable three-dimensional configuration of points of claim 17 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image
19. A machine-readable data storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of at least one molecule or molecular complex selected from the group consisting of:
(i) a molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP
binding pocket comprising the amino acids listed in Table 1, the TMP
binding pocket defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2;~
(ii) a molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket comprising the amino acids listed in Table 4, the TMP/ATP binding pocket defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2; and (iii) a molecule or molecular complex that is structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex, wherein the S. aureus thymidylate kinase molecule or molecular complex is represented by at least a portion of the structure coordinates listed in Figure 2.
(i) a molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP
binding pocket comprising the amino acids listed in Table 1, the TMP
binding pocket defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2;~
(ii) a molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket comprising the amino acids listed in Table 4, the TMP/ATP binding pocket defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2; and (iii) a molecule or molecular complex that is structurally homologous to an S. aureus thymidylate kinase molecule or molecular complex, wherein the S. aureus thymidylate kinase molecule or molecular complex is represented by at least a portion of the structure coordinates listed in Figure 2.
20. A machine-readable data storage medium comprising a data storage material encoded with a first set of machine readable data which, when combined with a second set of machine readable data, using a machine programmed with instructions for using said first set of data and said second set of data, can determine at least a portion of the structure coordinates corresponding to the second set of machine readable data, wherein said first set of data comprises a Fourier transform of at least a portion of the structural coordinates for S. aureus thymidylate kinase listed in Figure 2;
and said second set of data comprises an x-ray diffraction pattern of a molecule or molecular complex of unknown structure.
and said second set of data comprises an x-ray diffraction pattern of a molecule or molecular complex of unknown structure.
21. A method for obtaining structural information about a molecule or a molecular complex of unknown structure comprising:
crystallizing the molecule or molecular complex;
generating an x-ray diffraction pattern from the crystallized molecule or molecular complex;
applying at least a portion of the structure coordinates set forth Figure 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex whose structure is unknown.
crystallizing the molecule or molecular complex;
generating an x-ray diffraction pattern from the crystallized molecule or molecular complex;
applying at least a portion of the structure coordinates set forth Figure 2 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex whose structure is unknown.
22. A method for homology modeling an S. aureus thymidylate kinase homolog comprising:
aligning the amino acid sequence of an S. aureus thymidylate kinase homolog with an amino acid sequence of S. aureus thymidylate kinase and incorporating the sequence of the S. aureus thymidylate kinase homolog into a model of S. aureus thymidylate kinase derived from structure coordinates set forth in Figure 2 to yield a preliminary model of the S aureus thymidylate kinase homolog;
subjecting the preliminary model to energy minimization to yield an energy minimized model;
remodeling regions of the energy minimized model where stereochemistry restraints are violated to yield a final model of the S.
aureus thymidylate kinase homolog.
aligning the amino acid sequence of an S. aureus thymidylate kinase homolog with an amino acid sequence of S. aureus thymidylate kinase and incorporating the sequence of the S. aureus thymidylate kinase homolog into a model of S. aureus thymidylate kinase derived from structure coordinates set forth in Figure 2 to yield a preliminary model of the S aureus thymidylate kinase homolog;
subjecting the preliminary model to energy minimization to yield an energy minimized model;
remodeling regions of the energy minimized model where stereochemistry restraints are violated to yield a final model of the S.
aureus thymidylate kinase homolog.
23. A computer-assisted method for identifying an inhibitor of S. aureus thymidylate kinase activity comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, the TMP binding pocket comprising the amino acids listed in Table 1;
supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, the TMP binding pocket comprising the amino acids listed in Table 1;
supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
24. A computer-assisted method for identifying an inhibitor of S. aureus thymidylate kinase activity comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, the TMP/ATP
binding pocket comprising the amino acids listed in Table 4;
supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, the TMP/ATP
binding pocket comprising the amino acids listed in Table 4;
supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
25. The method of claim 23 wherein the TMP binding pocket comprises the amino acids listed in Table 1, the TMP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
26. The method of claim 24 wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 4, the TMP/ATP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
27. The method of claim 23 or 24 wherein determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the binding pocket.
28. The method of claim 23 or 24 further comprising screening a library of chemical entities.
29. A computer-assisted method for designing an inhibitor of S. aureus thymidylate kinase activity comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, the TMP binding pocket comprising the amino acids listed in Table 1;
supplying the computer modeling application with a set of structure coordinates for a chemical entity;
evaluating the potential binding interactions between the chemical entity and substrate binding pocket of the molecule or molecular complex;
structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, the TMP binding pocket comprising the amino acids listed in Table 1;
supplying the computer modeling application with a set of structure coordinates for a chemical entity;
evaluating the potential binding interactions between the chemical entity and substrate binding pocket of the molecule or molecular complex;
structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
30. A computer-assisted method for designing an inhibitor of S. aureus thymidylate kinase activity comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, the TMP/ATP
binding pocket comprising the amino acids listed in Table 4;
supplying the computer modeling application with a set of structure coordinates for a chemical entity;
evaluating the potential binding interactions between the chemical entity and substrate binding pocket of the molecule or molecular complex;
structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, the TMP/ATP
binding pocket comprising the amino acids listed in Table 4;
supplying the computer modeling application with a set of structure coordinates for a chemical entity;
evaluating the potential binding interactions between the chemical entity and substrate binding pocket of the molecule or molecular complex;
structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
31. The method of claim 29 wherein the TMP binding pocket comprises the amino acids listed in Table 1, the TMP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
32. The method of claim 30 wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 1, the TMP/ATP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
33. The method of claim 29 or 30 wherein determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the binding pocket.
34. The method of claim 29 or 30 wherein the set of structure coordinates for the chemical entity is obtained from a chemical fragment library
35. A computer-assisted method for designing an inhibitor of S. aureus thymidylate kinase activity de novo comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, wherein the TMP
substrate binding pocket comprises the amino acids listed in Table 1;
computationally building a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP binding pocket, wherein the TMP
substrate binding pocket comprises the amino acids listed in Table 1;
computationally building a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
36. A computer-assisted method for designing an inhibitor of S. aureus thymidylate kinase activity de novo comprising:
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 4;
computationally building a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus thymidylate kinase or thymidylate kinase-like TMP/ATP binding pocket, wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 4;
computationally building a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus thymidylate kinase activity.
37. The method of claim 35 wherein the TMP binding pocket comprises the amino acids listed in Table 1, the TMP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
38. The method of claim 36 wherein the TMP/ATP binding pocket comprises the amino acids listed in Table 4, the TMP/ATP binding pocket being defined by a set of points having a root mean square deviation of less than about 2.1 .ANG. from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 2.
39. The method of claim 35 or 36 wherein determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the binding pocket.
40. The method of any of claims 23, 24, 29, 30, 35, or 36 further comprising supplying or synthesizing the potential inhibitor, then assaying the potential inhibitor to determine whether it inhibits S. aureus TMK
activity.
activity.
41. A method for making an inhibitor of S aureus TMK activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus TMK activity, the chemical entity having been identified during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one of a S. aureus thymidylate kinase or thymidylate kinase-like TMP or TMP/ATP binding pocket; supplying the computer modeling application with a set of structure coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at a binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S.
aureus TMK activity.
aureus TMK activity.
42. A method for making an inhibitor of S. aureus TMK activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus TMK activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one of a S. aureus thymidylate kinase or thymidylate kinase-like TMP or TMP/ATP binding pocket; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and a binding pocket of the molecule or molecular complex; structurally modifying the chemical entity to yield a set of structure coordinates for a modified chemical entity; and determining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at the binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus TMK activity.
43. A method for making an inhibitor of S. aureus TMK activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus TMK activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of at least one of a S. aureus thymidylate kinase or thymidylate kinase-like TMP or TMP/ATP binding pocket; computationally building a chemical entity represented by set of structure coordinates; and determining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at a binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus TMK
activity.
activity.
44. An inhibitor of S. aureus thymidylate kinase activity identified, designed or made according to the method of any of the claims 23, 24, 29, 30, 35, 36, 41, 42, or 43.
45. A composition comprising an inhibitor of S. aureus thymidylate kinase activity identified or designed according to the method of any of the claims 23, 24, 29, 30, 35, 36, 41, 42, or 43.
46. A pharmaceutical composition comprising an inhibitor of S. aureus thymidylate kinase activity identified or designed according to the method of any of the claims 23, 24, 29, 30, 35, 36, 41, 42, or 43 or a salt thereof, and pharmaceutically acceptable carrier.
47. A method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex comprising:
preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml; and crystallizing S. aureus thymidylate kinase from a solution comprising about 5 wt. % to about 50 wt. % PEG, about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7.
preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml; and crystallizing S. aureus thymidylate kinase from a solution comprising about 5 wt. % to about 50 wt. % PEG, about 0.05 M to about 0.5 M MgCl2, and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7.
48. A method for crystallizing an S. aureus thymidylate kinase molecule or molecular complex comprising:
preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml; and crystallizing S. aureus thymidylate kinase from a solution comprising about 2 mM to about 20 mM .beta.,.gamma.-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7.
preparing purified S. aureus thymidylate kinase at a concentration of about 1 mg/ml to about 50 mg/ml; and crystallizing S. aureus thymidylate kinase from a solution comprising about 2 mM to about 20 mM .beta.,.gamma.-difluoromethylene-bisphosphonate adenosine monophosphate and about 0 wt. % to about 20 wt. % DMSO, wherein the solution is buffered to a pH of about 6 to about 7.
49. A crystal of S. aureus thymidylate kinase.
50. The crystal of claim 49 having the trigonal space group symmetry P2 1.
51. The crystal of claim 49 comprising a unit cell having dimensions of a, b, and c; wherein a is about 40 .ANG. to about 60 .ANG., b is about 80 .ANG. to about 100 .ANG., and c is about 40 .ANG. to about 60 .ANG.; and wherein a = .gamma. =
90° and .beta. is about 80° to about 120°.
90° and .beta. is about 80° to about 120°.
52. The crystal of claim 49 comprising atoms arranged in a spatial relationship represented by the structure coordinates listed in Figure 2.
53. The crystal of claim 49 having amino acid sequence SEQ ID NO:1.
54. The crystal of claim 49 having amino acid sequence SEQ ID NO:1, with the proviso that at least one methionine is replaced with selenomethionine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14711799P | 1999-08-04 | 1999-08-04 | |
US60/147,117 | 1999-08-04 | ||
PCT/US2000/021425 WO2001011025A2 (en) | 1999-08-04 | 2000-08-04 | Crystallization and structure determination of staphylococcus aureus thymidylate kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2378010A1 true CA2378010A1 (en) | 2001-02-15 |
Family
ID=22520348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002378010A Abandoned CA2378010A1 (en) | 1999-08-04 | 2000-08-04 | Crystallization and structure determination of staphylococcus aureus thymidylate kinase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1200565A2 (en) |
JP (1) | JP2003517818A (en) |
AU (1) | AU781654B2 (en) |
CA (1) | CA2378010A1 (en) |
WO (1) | WO2001011025A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525947A (en) * | 2003-05-07 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Methionine aminopeptidase and method of use thereof |
JP6026425B2 (en) * | 2010-11-02 | 2016-11-16 | プロビオドルグ エージー | Crystal structure of isoglutaminyl cyclase |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737248B2 (en) * | 1996-01-05 | 2004-05-18 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
CA2341311A1 (en) * | 1998-09-01 | 2000-03-09 | Human Genome Sciences, Inc. | Staphylococcus aureus genes and polypeptides |
-
2000
- 2000-08-04 WO PCT/US2000/021425 patent/WO2001011025A2/en not_active Application Discontinuation
- 2000-08-04 CA CA002378010A patent/CA2378010A1/en not_active Abandoned
- 2000-08-04 EP EP00953850A patent/EP1200565A2/en not_active Withdrawn
- 2000-08-04 AU AU66227/00A patent/AU781654B2/en not_active Ceased
- 2000-08-04 JP JP2001515812A patent/JP2003517818A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU781654B2 (en) | 2005-06-02 |
AU6622700A (en) | 2001-03-05 |
WO2001011025A2 (en) | 2001-02-15 |
JP2003517818A (en) | 2003-06-03 |
EP1200565A2 (en) | 2002-05-02 |
WO2001011025A3 (en) | 2001-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090062286A1 (en) | Crystal Structure of SMYD3 Protein | |
Sivaraman et al. | Crystal structure of histidinol phosphate aminotransferase (HisC) from Escherichia coli, and its covalent complex with pyridoxal-5′-phosphate and l-histidinol phosphate | |
WO2005113762A1 (en) | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF | |
US6387641B1 (en) | Crystallized P38 complexes | |
EP1578687A2 (en) | Crystalline structure of human mapkap kinase-2 | |
US8002891B2 (en) | Crystallization of C-Jun N-Terminal Kinase 3 (JNK3) | |
US6356845B1 (en) | Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB) | |
US6988041B2 (en) | Crystallization and structure determination of Staphylococcus aureus NAD synthetase | |
WO1999057253A2 (en) | Crystallizable jnk complexes | |
AU781654B2 (en) | Crystallization and structure determination of staphylococcus aureus thymidylate kinase | |
CA2376065A1 (en) | Crystallization and structure determination of staphylococcus aureus elongation factor p | |
US6689595B1 (en) | Crystallization and structure determination of Staphylococcus aureus thymidylate kinase | |
US20030165984A1 (en) | Hepatitis C virus helicase crystals, crystallographic structure and methods | |
US20030166843A1 (en) | Crystallization and structure determination of staphylococcus aureus thioredoxin reductase | |
US6484103B1 (en) | Crystal structure | |
US20050208639A1 (en) | Crystal structure of staphylococcus undecaprenyl pyrophosphate synthase and uses thereof | |
US20040191271A1 (en) | Crystal structures of streptococcus undecaprenyl pyrophosphate synthase and uses thereof | |
WO2002055550A2 (en) | Crystallization and structure determination of fema and/or fema-like proteins | |
JP2007522792A (en) | Crystal and structure of c-Ab1 tyrosine kinase domain | |
CA2440409A1 (en) | A crystal of bacterial core rna polymerase with rifampicin and methods of use thereof | |
EP1476840A2 (en) | Crystal structures of jnk-inhibitor complexes and binding pockets thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |